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acyltransferase   acyl coenzyme A isopenicillin N acyltransferase
AGA     N(4)-(!-N-acetylglucosaminyl)-L-asparaginase
CHO cells    Chinese hamster ovary cells
DNJ     deoxynojirimycin
EE     early endosome
EET     enzyme enhancement therapy
ER     endoplasmic reticulum
ERAD     endoplasmic reticulum associated degradation
ERT     enzyme replacement therapy
GAA     lysosomal "-glucosidase
GALNS    N-acetylgalactosamine-6-sulphatase
GH31      glycoside-hydrolase family 31
GLA     "-galactosidase A
Glc     glucose
GlcNAc    N-acetylglucosamine residue
GlcNAc phosphotransferase N-acetylglucosamine-1-phosphotransferase
LAMP-1     lysosome-associated membrane protein-1
LAMP-2    lysosome-associated membrane protein-2
LAMP-3    lysosome-associated membrane protein-3
LE     late endosome
LIMP-2     lysosome integral membrane protein 2
LSD     lysosomal storage disorder
Man     mannose
MAN2B1     lysosomal "-mannosidase
MGA     maltase-glucoamylase
M6P     mannose-6-phosphate
N-glycan    asparagine linked glycosylation
Ntn     N-terminal nucleophile
Ntn-hydrolase   N-terminal nucleophile aminohydrolase
PLB     phospholipase B
PLBD1     phospholipase B-like protein 1
bPLBD1     bovine phospholipase B-like protein 1
hPLPD1     human phospholipase B-like protein 1
PLBD2    phospholipase B-like protein 2
hPLBD2    human phospholipase B-like protein 2
mPLBD2    mouse phospholipase B-like protein 2
RE     recycling endosome
SL     secretory lysosome
UPS     ubiquitin proteasome system
Abbreviations of amino acids
A Ala Alanine
C Cys Cysteine
D Asp Aspartic acid
E Glu Glutamic acid
F Phe Phenylalanine
G Gly  Glycine
H His Histidine
I Ile Isoleucine
K Lys Lysine
M Met Methionine
N Asn Asparagine
P Pro Proline
Q Gln Glutamine
R Arg Arginine
S Ser  Serine
T Thr Threonine
W Trp Tryptophan
V Val Valine
Y Tyr Tyrosine
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Abstract
Lysosomes are membrane enclosed acidic cell organelles found ubiquitously  in 
higher eukaryotes. The lysosomal lumen contains more than 60 soluble lysosomal 
hydrolases, which degrade and recycle cellular macromolecules.  Mutations in genes 
encoding lysosomal or  lysosome related proteins result in over 50 different 
lysosomal storage disorders (LSDs) affecting 1  out of every  7700 newborn children. 
For  instance,  the first described LSD, Pompe disease, is caused by  a mutation that 
impairs the function of lysosomal !-glucosidase (GAA) and that results in 
lysosomal accumulation of glycogen. In this study, several lysosomal proteins were 
studied via a  variety  of techniques to increase the knowledge of lysosomal function 
and correspondingly, the lysosome associated diseases.
In order to better understand its function, the previously  not well characterised 
phospholipase B-like protein 1  (PLBD1) was purified from  bovine kidneys. It was 
crystallised and the structure solved by  X-ray  crystallography  to a 1.9 Å resolution. 
The structure showed that PLBD1  is a member of the N-terminal nucleophile 
aminohydrolases superfamily. This would imply  that  PLBD1 is not  an esterase as 
the name suggests, but an amidase. The finding that the hydrophobic tail of the 
potential phospholipid substrate does not fit into the acyl binding cavity  also argues 
against phosphoesterase function.
As a first step in the protein transport  pathway  to lysosomes mannose-6-
phosphate-tag is added to lysosomal proteins. This is initiated by  N-
acetylglucosamine-1-phosphotransferase (GlcNAc phosphotransferase), which 
requires a recognition signal on the folded surface of the lysosomal proteins. In this 
study, the conservation of the signal in four lysosomal proteins was analysed.  The 
phosphorylated N-glycosylation sites and the lysine residues on the GlcNAc 
phosphotransferase recognition site are well conserved at the sequence level in 
orthologous proteins, but  not necessarily  in the protein family. Based on surface 
analysis of PLBD1  and comparison to the paralogous PLBD2, the most likely 
recognition site for  the GlcNAc phosphotransferase for the PLBD1  could be 
suggested.
LSD associated mutations affect protein function through several mechanism. 
Several disease-associated missense mutations disturb the protein fold. A general 
analysis of four enzymes associated with LSD showed that the disease-associated 
missense mutations are not equally  distributed among the 20 amino acids. Glycine, 
arginine and proline are clearly  over-represented among the mutations compared 
to their  abundance in protein sequences.  The hydrophobic amino acids tend to be 
under-represented among disease-associated mutations.  The amino acids where 
mutation frequently  involves a disease have unique properties that  contribute to 
the protein structure in a way that cannot be compensated by other amino acids.
Enzyme enhancement therapy  with chemical chaperones is a novel treatment for 
LSDs and has shown potential also for  Pompe disease. In this study, the 
stabilisation capacity  of potential chemical chaperones for  GAA were tested. Most 
of the compounds stabilised rhGAA against thermal unfolding and some stabilised 
even better than would be expected from their binding affinity. In addition, the 
compounds were modelled to the active site of a  GAA structural model and based 
on this three factors to be considered in chemical chaperone design were defined. 
Firstly, the ligand size can vary, but the four OH-groups in the ligand are critical in 
orienting  the molecule and making the binding specific. Last but most importantly, 
a positive charge and its location determine the strength of binding to GAA.
This thesis with  its structural studies of lysosomal proteins provides molecular 
understanding of lysosomal protein biology, which is critical for full  understanding 
lysosome function and its involvement in diseases.
1 Introduction
In each of the three domains of life, bacteria, archaea and eukaryota, the cell is the 
basic unit of life. Eukaryotic cells are distinct in that in all of them, different 
cellular  functions are arranged to distinct compartments called cell organelles.  In 
multicellular organisms, the diversity  of cell organelles facilitates specialisation of 
the cells to different roles. Most cells share a critical set of organelles for their 
basic functions. In animal cells, the lysosome, the main degradative compartment 
of the cell, is one of them.
Lysosomes were discovered in the 1950’s when Christian de Duve used tissue 
fractionation to characterise hepatic glucose-6-phosphatase (de Duve et al.,  1955). 
He named the ‘acid precipitable cell structures‘ as lysosomes, after the Greek 
words for  a  ‘digestive body’ (de Duve et al.,  1955; de Duve, 2005).  de Duve 
received a  Nobel prize of Physiology  and Medicine for his findings in 1974. The 
first  lysosomal storage disorder was described by  H. G. Hers in 1963, when he 
reported the absence of lysosomal !-glucosidase in Pompe disease (Hers, 1963).
In the case of the lysosome, the separation of the organelle’s functions from the 
rest of the cell has several advantages. The membrane of a lysosome limits the 
hydrolytic activities of the lysosomal enzymes to the lumenal side, and so protects 
other cell components from  non-specific hydrolysis. The separate compartment 
also allows the maintenance of the acidic environment in the lysosomal lumen, 
which is beneficial for the hydrolytic processes. In addition, since transport of 
molecules to lysosomes is highly  controlled, cells can regulate what  is hydrolysed 
and when the hydrolysis takes place. Thus, degradation can be used both for 
recycling and regulation purposes.
The lysosomal lumen is now known to contain more than 60 soluble lysosomal 
hydrolases. They  are a versatile group of mostly  unrelated proteins,  of which some 
are quite well characterised, such as the lysosomal !-glucosidase. Nonetheless, 
there are still poorly  understood proteins, such as the the phospholipase B-like 
protein 1, described in this study.  It  is also very  likely  that not all of the lysosomal 
proteins with hydrolytic activity have yet been identified.
Structural biology  addresses the questions on molecular  and structural basis of 
biology,  through the three dimensional structures of biological macromolecules. 
The information gained in structural biology  forms a  strong basis for most protein 
research. X-ray  crystallography  is the standard method for  solving three 
dimensional structures of proteins at atomic resolution.
*"
Today, the structures of approximately  two thirds of the more than 60 soluble 
lysosomal hydrolases are known and the atomic coordinates are available in the 
protein databank (www.rcsb.org; Berman et al.,  2000). The analysis of lysosomal 
protein structures benefits research both in biological and medical problems on 
lysosomes. For  instance, protein structures give insight to lysosomal protein 
processing (Coulombe et al.,  1996), low pH activation (Heikinheimo et al.,  2003) 
and transport to lysosomes (Steet et al., 2005; Warner  et al., 2002).  Important 
clues of the active site location and the catalytic mechanism of several hydrolases, 
such  as N(4)-(!-N-acetylglucosaminyl)-L-asparaginase (AGA) (Oinonen et al., 
1995) and arylsulfatase A (Lukatela et al., 1998), are derived from  the analysis of 
the protein structures. In addition, protein structures have provided insight to the 
molecular basis for several LSDs such  as "-mannosidosis (Kuokkanen et al., 2011) 
and Schindler and Kanzaki diseases (Clark and Garman,  2009). In addition, the 
development of therapeutic approaches for  LSDs, such as the enzyme 
enhancement therapy  (EET), has used structural information as a basis for 
understanding the mode of action (Parenti, 2009).
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2 Review of the literature
2.1 Role of lysosome in cells
Lysosomes are membrane enclosed cell organelles found ubiquitously  in higher 
eukaryotes. Their number differs greatly  between cells. In addition, the 
morphology  and size of individual lysosomes varies even inside the same cell 
(Figure 1). Lysosomes are characterised by  low pH and by  the presence of several 
hydrolases with optimum  activity  at acidic pH (Schröder et al.,  2010). The 
hydrolases are the key  for  the main function of the lysosome, which is the 
breakdown and recycling of cellular macromolecules.
The material that is degraded in lysosomes is diverse and includes proteins, 
sugars, macromolecular assemblies, worn out  cell organelles and microbes. 
Several pathways deliver material to lysosomes. The main pathways for 
internalised extracellular  and cell surface material are the endocytic pathways 
(Straus, 1958; de Duve and Wattiaux, 1966; Luzio et al.,  2009) and for the 
intracellular material the autophagy  pathways (Hruban et al., 1963; de Duve and 
!#
Figure 1. Electron micrograph of mouse embryonic fibroblasts. Lysosomes appear as 
electron dense globular bodies in electron micrographs. Depending on their content they 
can be multilaminar, have a fairly homogenous appearance, or have distinct vesicles 
inside them. ER stands for endoplasmic reticulum M for Mitochondrion and L for 
lysosomes. The electron micrograph was kindly provided by Dr. Eeva-Liisa Eskelinen, 
Department of Biosciences, University of Helsinki, Finland.

most genes related to the formation and function of lysosomes have coordinated 
expression, which  is regulated by  the transcription factor  EB (Sardiello et al., 
2009).
Since they  were discovered, lysosomes have been recognised to be involved in 
many  functions in the cell. For instance, the nervous system  develops and 
maintains neurons by  trafficking and degrading neurotrophic factors and their 
receptors through the endocytic pathway  (Glerup et al., 2013). In thyroids, 
endocytosis is used to process the prohormone thyroglobulin (Friedrichs et al., 
2003).  Secretory  lysosomes and phagosomes function mostly  in the cells of the 
immune system. Cytotoxic T-cells use their  secretory  lysosomes, the lytic granules, 
for  target cell killing (Russell and Ley, 2002). Neutrophils utilise both 
phagocytosis and secretory  lysosomes for  pathogen killing (Lee et al., 2003) as do 
macrophages although by  different mechanisms. In osteoblasts,  secretory 
lysosomes are involved in bone resorption (Baron et al.,  1985). Phagocytosis is 
used also by  non immune system cells such as fibroblasts to ingest apoptotic cells 
and thus participate in cell turn over (Elliott and Ravichandran, 2010).
Thus, in addition to their basic degradative function,  lysosomes have important 
maintenance function in multicellular organisms. Lysosomes are involved at least 
in  bone and tissue homeostasis and remodelling, cholesterol homeostasis, 
immunodefence, cell signalling and hormone and growth factor regulation.
2.2. Soluble lysosomal protein synthesis and transport
2.2.1 Synthesis and post translational modifications
Lysosomal proteins are synthesised through  the secretory  pathway. The signal 
recognition particle arrests the elongation of the polypeptide by  binding the N-
terminal signal sequence of the lysosomal protein. The ribosome in complex with 
the nascent  polypeptide is then targeted to the ER membrane (Wiedmann et al., 
1987; Ataide et al.,  2011), where the Sec61-translocon co-translationally  directs 
the nascent polypeptide into the ER lumen (Simon and Blobel, 1991; Osborne et 
al., 2005).
Folding of the nascent polypeptide begins as soon as the first part of it  reaches the 
ER lumen (Kowarik et al., 2002) and the folding  process is assisted by  several 
molecular chaperones (Jansen et al.,  2012). All lysosomal hydrolases have 
modifications, such as proteolytic processing, formation of disulphide bridges and 
glycosylation (Schröder et al., 2010). Even though many  of the polypeptide 
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modifications happen co-translationally  (Kowarik et al., 2002), they  are 
commonly referred to as post translational modifications.
Cleavage of the signal sequence in the ER is the first  proteolytic processing step 
for  lysosomal proteins. Many  lysosomal proteins have several additional 
proteolytic cleavages, which are required for formation of the mature protein 
(Schröder  et al., 2010). These proteolytic cuts mostly  appear in later parts of the 
transport route (Hansen et al., 2004; Moreland et al., 2005).
Disulphide bonds are covalent  bonds between the side chains of two cysteine 
residues, which  increase protein stability  (Matsumura et al., 1989). Lysosomal 
hydrolases typically  contain disulphide bonds, and the formation of protein-
specific disulphide patterns is catalysed by  the multifunctional protein disulphide 
isomerase.  Protein disulphide isomerase is capable of both breaking and 
rearrangement of the disulphide bonds (Lambert and Freedman, 1985).
Eukaryotic proteins contain  two major types of glycosylation, O- and N-
glycosylation, which are named after their glycosidic linkages to the protein.  In 
lysosomal proteins, O-glycosylation occurs mainly  on membrane proteins, but the 
majority  of soluble lysosomal proteins contain several N-glycans (Kollmann et al., 
2005; Sleat et al., 2008). Protein N-glycosylation affects protein folding  (Shental-
Bechor  and Levy, 2008; Hanson et al., 2009),  solubility  (Shental-Bechor and 
Levy, 2008), transport (Braulke and Bonifacino, 2009) and stability  (Wormald 
and Dwek, 1999; Hanson et al., 2009).
N-glycosylation is a  sequential process. It starts in the ER with the addition of a 
dolichylpyrophosphate activated oligosaccharide to the nascent polypeptide 
(Burda and Aebi,  1999). The preassembled oligosaccharide has a conserved 
structure consisting of three glucose (Glc), nine mannose (Man) and two N-
acetylglucosamine (GlcNAc) residues (Figure 3) (Burda and Aebi, 1999). 
Membrane bound oligosaccharyl transferase transfers the activated 
oligosaccharide from  the lipid carrier to the amide group of an asparagine residue 
(Roboti and High, 2012) (Figure 3).  This asparagine needs to be part  of the 
consensus sequence Asn-X-Ser/Thr, where X can be any  amino acid except a 
proline (Figure 3) (Bause, 1983). Mouse glycoproteomic studies have shown that 
N-glycosylation on Asn-X-Cys and other motifs also occurs occasionally  (Zielinska 
et al., 2010).
Most, but not all potential N-glycosylation sites are glycosylated in vivo. The 
activity  of the oligosaccharyl transferase is affected by  the local conformation of 
the glycosylation area (Bause, 1983; Zielinska et al., 2010). N-glycans are mostly 
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N-glycosylation is tightly  linked to glycoprotein folding and ER quality  control. N-
glycosylation happens co-translationally  (Helenius and Aebi, 2004; Harada et al., 
2009) and the N-glycosylation directly  affects the folding process through the 
physico-chemical properties of the glycan (Shental-Bechor and Levy, 2008; 
Hanson et al., 2009).
The glycans also affect the protein  folding process indirectly  through the calnexin/
calreticulin  cycle (Hammond et al., 1994).  The N-glycan modification starts 
during the translation when the outermost and the following glucose residues of 
Glc3Man9GlcNAc2 are removed by  glucosidase I and glucosidase II (Figure 3) 
(Aebi et al., 2010).  The revealed Glc1Man9GlcNAc2 is recognised by  a  membrane 
bound calnexin or  its soluble homolog calreticulin (Caramelo and Parodi, 2008). 
These two ER resident  lectins prevent the aggregation or premature ER exit of the 
polypeptide as it folds.
The exact  composition of the protein  glycan works as a signal that  reflects the 
folding status of the protein (Helenius and Aebi, 2004). When glucosidase II 
removes the final glucose residue from  the Glc1Man9GlcNAc2 the protein is 
released from the lectin (Caramelo and Parodi, 2008).  The enzyme UDP-
Glc:glycoprotein glucosyltransferase Glucosidase II works as a  conformation 
sensor  and if the protein  is incorrectly  folded it reglucosylates the Man9GlcNAc2 
glycan (Sousa and Parodi,  1995). As a result of the reglucosylation, the 
glycoprotein rebinds calnexin/calreticulin. This cycle of re- and deglucosylation 
associated with binding and release of calnexin/calreticulin continues until the 
protein is correctly folded or the folding is terminally unsuccessful.
When not bound to the calnexin/calreticulin, the N-glycans are exposed to the 
activity  of the ER mannosyl-oligosaccharide 1,2-!-mannosidase. It removes the 
terminal mannose residue from the middle branch, resulting in  Man8GlcNAc2 
glycans (Figure 3) (Moremen and Molinari,  2006). Proteins staying longer in the 
re/deglucosylation cycle under further  demannosylation as mannosyl-
oligosaccharide 1,2-!-mannosidase continues removing mannose residues one by 
one resulting in Man5-6GlcNAc2 glycans, which are less attractive target for ER-
exit and more likely  to be passed to the ERAD system (Lederkremer and 
Glickman, 2005).
After the ER, the Man8GlcNAc2  glycans are further trimmed in the Golgi 
(Moremen et al., 1994; Moremen, 2002). These modifications are needed for 
transport  of lysosomal proteins and they  produce important  additional structural 
complexity in the glycoproteins (Gabius et al., 2011).
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2.2.3 M6P-dependent pathway
The mannose-6-phosphate (M6P)-dependent pathway  is the best  characterised 
and the major  route for transport  of soluble proteins to lysosomes. The M6P-tag is 
added to the glycans on lysosomal proteins in a two step process in  the cis-Golgi 
(Pohlmann et al., 1982). The enzyme N-acetylglucosamine-1-phosphotransferase 
(GlcNAc phosphotransferase) recognises lysosomal proteins and transfers a 
GlcNAc-1-phosphate group to the  C6 hydroxyl group of selected mannose 
residues on lysosomal proteins (Figure 3)(Bao et al., 1996). The number of 
phosphorylated N-glycans is protein specific and each N-glycan can be mono- or 
diphosphorylated (Varki and Kornfeld, 1980). A second enzyme, N-
acetylglucosamine-1-phosphodiester  "-N-acetylglucos-aminidase, removes the 
terminal GlcNAc residue thus uncovering the M6P group (Figure 3) (Kornfeld et 
al.,  1999). The incompletely  or  non-phosphorylated polymannose glycans can be 
further modified to hybrid or complex type glycans (Moremen, 2002).
The labelled lysosomal proteins bind to the M6P-receptors in the trans-Golgi.  The 
two M6P receptors,  cation-dependent mannose-6-phosphate receptor  (Olson et 
al.,  1999) and cation-independent mannose-6-phosphate receptor  (Zhou et al., 
1995),  complement  each  other,  and are both required for lysosomal transport  via 
the M6P pathway  (Pohlmann et al., 1995). The M6P receptors and their  cargo are 
transported through the endo-lysosomal pathway  to lysosomes (Olson et al., 1999)
(Figure 1). The pH of the endosomal vesicles is gradually  decreased during the 
pathway, and at low pH of late endosomes, the M6P receptors release their cargo. 
The M6P tags are rapidly  removed soon after arrival of the protein in the lysosome 
(Makrypidi et al.,  2012).  The empty  M6P receptors cycle back from  the late 
endosomes to the trans-Golgi or  to the cell membrane (Dahms et al., 2008). 
Mistakenly  secreted M6P-tagged proteins are recaptured on the cell surface by  the 
cation-independent mannose-6-phosphate receptors and with it they  are then 
delivered through endocytosis back to the lysosome (Pohlmann et al., 1995). This 
feature is utilised in enzyme replacement therapy  for lysosomal storage disorders 
(Brady, 2006).
Recognition of the lysosomal proteins for  the M6P-dependent pathway  is not 
based on a simple signal sequence. Instead, the recognition is dependent on the 
folded protein surface, which  is recognised by  GlcNAc phosphotransferase 
(Reitman and Kornfeld, 1981).
The recognition motif for  GlcNAc phosphotransferase is known only  for a  limited 
number of lysosomal proteins (Table 1).  In cathepsin D and L, two surface lysine 
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To date two main receptors for the M6P-independent pathway  have been 
identified, sortilin and lysosomal integral membrane protein type 2 (LIMP-2) 
(Coutinho et al., 2012). The mechanism of intracellular targeting of 
glucosylceramidase to lysosomes was unclear  until Reczek and coworkers 
identified LIMP-2 association with glucosylceramidase (Reczek et al., 2007). As 
with  other  lysosomal membrane proteins,  LIMP-2  is directed from the trans-Golgi 
to lysosomes by  the cytosolic signal sequence and transported in clathrin-coated 
vesicles (Vega  et al., 1991). LIMP-2 binds to soluble glucosylceramidase in a pH-
dependent manner,  and the release of glucosylceramidase occurs when LIMP-2 
arrives in the acidic lysosome (Zachos et al., 2012).
Sortilin has been proposed to be involved in the transport of several lysosomal 
proteins such as prosaposin and Ganglioside GM2  activator, acid spingomyelinase 
and cathepsin D and H (Petersen et al.,  1997; Lefrancois et al.,  2003; Canuel et 
al.,  2008). Sortilin  is a multifunctional protein involved in many  other  processes 
in  addition to the lysosomal transport, such as signal transduction (Nykjaer et al., 
2004). It is highly  expressed in many  cell types, but especially  in brain (Petersen 
et al., 1997).
2.3 Lysosomal proteins
The lysosomal proteome contains both soluble and membrane bound proteins, 
most of which are unique for lysosomes (Schröder  et al.,  2010).  The hydrolytic 
function is concentrated in the lysosomal lumen and thus most lysosomal 
hydrolases are soluble proteins (discussed in more detail in section 2.3.2).  In 
addition to the hydrolases,  the lumen contains some other proteins that  assist 
hydrolysis. The function of the lysosomal limiting membrane and the proteins 
within is to separate the lysosomal activities from the cell cytosol, control the 
fusion of lysosomes with other  cell organelles and regulate the lysosomal content 
by bidirectional selective transport of molecules.
2.3.1 Proteins of lysosomal membrane
The lysosomal lipid bilayer has a specific phospholipid composition compared to 
other membranes in the animal cell (Gallegos et al., 2002) and its cholesterol 
concentration is lower  than in the plasma membrane or late endosomes (Hamer  et 
al., 2012).
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The limiting lysosomal membrane contains at least 100 different proteins, 
including both transmembrane and membrane associated proteins (Schwake et 
al.,  2013). Many  of the lysosomal membrane proteins have been characterised 
only  in recent years due to their hydrophobic nature and low abundance. The 
specific function of all of them is not yet clear, and many are multifunctional.
One of the key  proteins in the lysosomal membrane is the vacuolar ATPase. It  is a 
large multimeric proton-pump, which is essential for  the lysosomal function as it 
keeps the interior of the lysosomes at pH of 4.6-5.0 (Mellman et al.,  1986).  The 
low pH makes the hydrolytic process more effective. The low pH optimum  of 
lysosomal hydrolases also makes unwanted hydrolytic activity  less likely  during 
transport of nascent lysosomal proteins to lysosomes.
The most abundant lysosomal membrane proteins are the lysosome-associated 
membrane proteins-1  and -2  (LAMP-1  and LAMP-2). Because of their  high 
abundance on lysosomal membranes in most tissue types, LAMP-1  and LAMP-2 
are used as lysosomal markers in cell biology. LAMP-3 is a cell type specific 
protein found only  in mature human dendritic cells (de Saint-Vis et al., 1998). 
LAMPs are heavily  glycosylated and they  form  a  glycocalyx-like coating on the 
lumenal side of the lysosomal membrane, which is believed to protect the 
lysosomal membrane from  degradation (Wilke et al., 2012). LAMP proteins are 
also known to be involved in lysosomal biogenesis, phagocytosis (Eskelinen and 
Saftig, 2009) and in cholesterol transport (Schneede et al., 2011). Several other 
functions are probably still to be discovered.
LAMP-1  and LAMP-2 proteins are type I transmembrane proteins with one 
membrane spanning domain, a short cytosolic tail and a large lumenal domain. 
Glycosylation raises their molecular weight from  the predicted 40-45 kDa to the 
observed 120 kDa (Carlsson et al.,  1988). LAMP-2 pre-RNA can be alternatively 
spliced into three different isoforms that have changes both in transmembrane 
and cytosolic domains (Hatem et al., 1995). The structure of the membrane 
proximal domain of the human LAMP-3 is known (Wilke et al., 2012) and the 
LAMP-1  and LAMP-2  lumenal domains have been modelled based on the LAMP-3 
structure(Wilke et al., 2012).
Lysosomal integral membrane protein type 2 (LIMP-2) is heavily  glycosylated and 
the abundant type III transmembrane protein (Fujita et al.,  1991) is involved in 
the delivery  of glucosylceramidase from  trans-Golgi to the lysosomes(Reczek et 
al., 2007).
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Transporter proteins on the membrane enclosing the lysosome transport 
lysosomal substrates and degradation products across the membrane. For 
example,  the limiting membrane contains several amino acid transporters, such as 
the proton-coupled amino acid transporter 1  (Sagné et al., 2001), which transports 
small neutral amino acids. Sialin is a  transporter  which was identified from 
Finnish  disease heritage studies for Salla disease (Aula et al., 1979; Mancini et al., 
1991). Sialin is a H+ and sugar symporter, which exports sialic acid and acidic 
hexoses from lysosomes to the cytosol and imports asparagine and glutamine 
(Saftig and Klumperman, 2009).
The lysosomal membrane also contains a few  enzymes, such  as the heparan-"-
glucosaminide N-acetyltransferase (Durand et al.,  2010). This enzyme transfers 
an acetyl group from  cytoplasmic acetyl-CoA to the terminal N-glucosamine 
residues of heparan sulphate within the lysosomes. The reaction is crucial for 
heparin degradation and lack of the activity  causes lysosomal excess of stored 
heparin in mucopolysaccharidosis IIIC (Durand et al., 2010).
2.3.2 Soluble lysosomal hydrolases
The over  60 known soluble lysosomal proteins are more extensively  characterised 
than the membrane embedded lysosomal proteins because they  are often 
abundant and relatively  easy  to isolate. Several lysosomal proteins have been 
recognised through lysosomal storage disorders and genome studies. In addition, 
proteomic analysis has identified several novel candidates for soluble proteins in 
the lysosomal lumen (Kollmann et al., 2005; Schröder et al., 2010).
Lysosomal proteins degrade many  types of macromolecules down to simple 
components such as monosaccharides, fatty  acids and amino acids. Each 
hydrolase has a  specific activity, and the degradation of most compounds is a 
highly  organised multistep process, where the hydrolases work in a  concerted 
manner.  The lysosomal hydrolases can be classified on the basis of sequence or 
structural similarity,  linked LSD (for example CLN1-8 proteins),  catalytic activity 
or substrate (EC numbering). Based on substrate specificity, most lysosomal 
hydrolases fall into one the following groups: proteases, lipases,  glycosidases, 
phosphatases, sulphatases and nucleases (Table 2).
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Substrate 
specificity
Example proteins Involved in
Lipases
Phospholipases
Lysosomal Group XV phospholipase A 
(UniProt Q8NCC3)
Degradation of 
phospholipids
Phospholipase D1                                  
(UniProt Q13393)
Degradation of 
phospholipids
Sphingo-
myelinases
Sphingomyelin phosphodiesterase 
(UniProt P17405)
Degradation of 
sphingomyelin
Ceramidases Acid ceramidase                                     
(UniProt Q13510)
Degradation of 
ceramide
Cholesteryl 
esterase
Lysosomal acid lipase/cholesteryl ester 
hydrolase (UniProt P38571)
Degradation of 
cholesteryl esters
Glycosidases
Acid "-glucosidase                                 
(UniProt P10253)
Degradation of 
glycogen
Hyaluronidase-1                                  
(UniProt Q12794)
Degradation of 
hyaluronan
"-L-iduronidase                                   
(UniProt P35475)
Degradation of 
dermatan and 
heparan sulphates
!-glucuronidase                          
(UniProt P08236)
Degradation of 
dermatan and 
keratan sulphates
!-galactosidase                          
(UniProt P16278)
Degradation of 
glycosphingolipids, 
glycoproteins, 
glycosaminoglycans
Sialidase-1                                  
(UniProt Q99519)
Degradation of 
oligosaccharides, 
gangliosides and 
glycoproteins
!-hexoaminidases A, B, S                      
(UniProt P06865 for subunit ", P07686 
for subunit !)
Degradation of 
proteoglycans, 
glycolipids and 
glycoproteins
Galactocerebrosidase                         
(UniProt P54803)
Degradation of 
galactosphingolipids


2.3.2.1 Proteases
Lysosomes contain more than 15 different proteases: they  are involved both in the 
bulk degradation of proteins and in  more specialised functions in many  cellular 
processes (Müller  et al., 2012). Most  lysosomal proteases belong to the cathepsin 
family. Tripeptidyl-peptidase 1  (UniProt O14773  ) is one of the few lysosomal non-
cathepsin proteases. It is a serine protease that cleaves tripeptides from  the N-
terminus of polypeptides in lysosomes (Lin et al., 2001).
Cathepsin proteases are divided based on sequence similarity  into serine, aspartic 
and cysteine cathepsins and the same divisions hold also for structure and 
catalytic type (Rawlings et al., 2013).  A  few of the cathepsins, such as dipeptidyl-
peptidase 1  (cathepsin C, UniProt P53634) are better  known by  their non-
cathepsin name. Many  lysosomal cathepsins are synthesised as procathepsins 
containing a propeptide (often a long loop) that needs to be removed in order for 
the enzyme to become catalytically active (Turk et al., 2012).
Cathepsin A (UniProt P10619) and cathepsin D (UniProt P07339) are the only 
known lysosomal members in their prospective cathepsin families. Cathepsin A, 
also known as lysosomal protective protein (Galjart et al., 1991) is a serine 
cathepsin. It is required for  the transport  of sialidase-1  to lysosomes and, together 
with  !-galactosidase, the three proteins form a  multi-enzyme complex (van der 
Spoel et al., 1998).
Cathepsin D is an aspartic cathepsin essential for instance in macroautophagy 
(Shacka et al., 2007) and is needed in the cleavage of apolipoprotein B in 
lysosomal low-density  lipoprotein degradation (Van Lenten and Fogelman, 1990). 
It  consists of two polypeptide chains linked by  disulphide bridges (Baldwin et al., 
1993). Cathepsin D has a typical aspartic protease fold (Table 2) with three 
domains; the central antiparallel !-sheet domain has N-and C-terminal lobes on 
both sides (Baldwin et al., 1993). Both of these lobes contain one N-glycan that 
can be phosphorylated (Cuozzo et al., 1998).
Cysteine cathepsins are members of the C1  family  of papain-like enzymes (Turk et 
al.,  2012) and the largest group of proteases in lysosomes (Rawlings et al., 2013). 
They  include cathepsin B (UniProt  P07858), cathepsin  C (dipeptidyl-peptidase 1), 
cathepsin F (UniProt Q9UBX1), cathepsin H (UniProt P09668), cathepsin K 
(UniProt P43235), cathepsin S (UniProt P25774) and cathepsins L1  (UniProt 
P07711) and L2  (UniProt O60911).  Cathepsin L2 is also known as cathepsin U or 
cathepsin V.
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Most cysteine cathepsins are ubiquitously  expressed, but the ones with more 
specialised roles can be expressed only  in few tissues. For example,  cathepsin B, 
which possesses both  endopeptidase and dipeptidyl carboxypeptidase activities, is 
ubiquitously  expressed (Rawlings et al., 2013), in contrast to cathepsin K, which  is 
involved in bone resorption (Saftig et al., 1998).  Cathepsin L1  and L2 have about 
70 % sequence identity,  but only  L2  expression is restricted to thymus and testis 
(Coulombe et al., 1996; Brömme et al., 1999).
The papain fold of cysteine cathepsins is formed by  two domains (Table 2), which 
are named left and right . The left domain contains three helices and the right 
domain is formed by  a kind of a !-barrel (Turk et al.,  2012). The active site 
catalytic histidine and cysteine residues and the residues interacting with the 
main chain of the substrate are conserved in the cysteine cathepsin family  (Turk et 
al.,  2012). The active site cleft is located at the interface of the two domains and it 
runs the full length of the interface in cysteine cathepsins that have predominantly 
endopeptidase activity  (cathepsins F, L1, L2, and S)(Turk et al., 2001). In 
cathepsin C, the active site cleft is modified by  an additional domain to provide 
exopeptidase specificity (Turk et al., 2001).
2.3.2.2 Glycosidases
Lysosomes receive carbohydrates as pure large polymers, such as glycogen and 
hyaluronan, or as glycoconjugates of lipids and proteins.
Some of the large polymeric carbohydrates, such as glycogen, are degraded by  a 
single enzyme, in some occasions with a help of a few  additional enzymes 
specialised for  a  particular  glycosidic bond or  substrate. The myriad of glycosidic 
linkages in  the glycolipid and glycoprotein conjugates,  requires several different 
glycosidases for a  complete hydrolysis; only  a handful of glycosidases act on both 
glycolipids and glycoproteins.  Due to this, degradation of glycoconjugates follows 
a more strict sequential pathway  than, for  example, degradation of proteins.  In 
addition,  hydrolysis of the glycosidic bonds in  glycolipids, requires several 
activator  proteins, and the lipid moiety  is usually  left  intact  in lysosomes until all 
glycosidic bonds are hydrolased (Schulze and Sandhoff,  2011). Conversely, most 
lysosomal glycosidases have low  activity  on intact glycoproteins, suggesting that at 
least partial proteolysis must precede the action of glycosidases (Winchester, 
2005).
Large polymer degradation
Glycogen degradation by lysosomal "-glucosidase is described in section 2.3.2.6.
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Hyaluronan is a linear extracellular  matrix glucosaminoglycan found in  most 
tissues (Laurent and Fraser, 1992) and it  is composed of disaccharide units of D-
glucuronic acid and N-acetyl-D-glucosamine linked together with !(1->3) and !(1-
>4) glycosidic bonds.  Of the five homologous human hyaluronidases,  one is 
lysosomal. Hyaluronidase-1  (UniProt Q12794),  cleaves the hyaluronan !(1->4) 
glycosidic bonds in lysosomes. Hyaluronidase-1  is endo-!-N-acetyl-
hexosaminidase, and its activity  results oligosaccharides of various lengths, which 
are probably  further  cleaved to monosachharides by  ! -exoglycosidases (Stern and 
Jedrzejas,  2006). Hyaluronidase-1  is formed by  the N-terminal catalytic domain 
with  a  distorted ("/!)8 -barrel fold and a  small C-terminal domain with an EGF 
like fold and three disulphide bridges.
"-L-iduronidase (UniProt  P35475) and !-glucuronidase (UniProt P08236) are 
involved in mucopolysaccharide degradation. Mucopolysaccharides, also known 
as glucosaminoglycans are major  components of the extracellular  matrix. 
Mucopolysaccharides consist  of repeating disaccharide units that form long 
unbranched chains.  "-L-iduronidase hydrolases the nonreducing terminal "-L-
iduronide glycosidic bond in the sulphated mucopolysaccharides dermatan 
sulphate and heparan sulphate (Scott et al., 1991).
Lipid conjugate deglycosylation
The lipid conjugates in eukaryotic cells are glycosphingolipids. They  are composed 
of a carbohydrate headgroup linked by  a  !-glycosidic bond to a  ceramide 
molecule. Cerebrosides are the simplest glycosphingolipids: they  have only  one 
sugar residue,  which can be either glucose or  galactose.  Gangliosides have more 
complex  carbohydrates, as their oligosaccharides are branched and contain at 
least three sugar  residues of which one must be sialic acid. The sequential removal 
of sugar residues begins from the terminal residues.
!-galactosidase (Uniprot P16278) cleaves the terminal !-galactose of 
glycospingolipids such as GM1  ganglioside,  glycoproteins and glucosaminoglycans 
(Distler  and Jourdian, 1973). The !-galactosidase dimer  has an N-terminal ("/!)8 
domain and two smaller !-sheet domains (Table 2)(Ohto et al.,  2012). !-
galactosidase is part of the same multi-enzyme complex  as cathepsin A  (van der 
Spoel et al., 1998) and the complex is required for  the proper processing and 
activity  of !-galactosidase (Hoogeveen et al.,  1986). The third member  of the 
multi-enzyme complex, sialidase-1  (Uniprot Q99519),  similarly  requires formation 
of the complex for full activity. Sialidase-1  removes the terminal sialic acid 
"!
residues from oligosaccharides, gangliosides, and glycoproteins (Bonten et al., 
1996).
The !-hexosaminidases A, B and S are dimeric enzymes that are formed of two 
subunits,  " (UniProt P06865) and ! (UniProt P07686), which have ~60% 
sequence identity  to each other (Korneluk et al., 1986).  Only  the dimers are 
catalytically  active (Maier et al.,  2003). !-hexosaminidase A is an "! heterodimer; 
!-hexosaminidase B is a !2 homodimer; -and !-hexosaminidase S, an "2 
homodimer.  !-hexosaminidases cleave terminal !-glycosidically  linked N-
acetylglucosamine or N-acetylgalactosamine residues from proteoglycans, 
glycolipids and glycoproteins (Maier  et al., 2003). They  are indispensable 
especially  in the degradation of gangliosides, which also requies the ganglioside 
GM2 activator (UniProt P17900), a small lipid carrier (Wright et al., 2000).
"-galactosidase A (GLA, Uniprot P06280) hydrolases terminal "-galactose 
linkages in various glycoconjugates (Lemansky  et al.,  1987). The predominant 
glycolipid substrate of GLA is globotriaosylceramide,  which  has three galactose 
residues linked to each other  by  1,4-glycosidic bonds. GLA is a homodimer  with 
two domains in each  monomer (Garman and Garboczi,  2004). The active site is a 
large opening located in the C-terminal end of the ("/!)8 barrel.  The structure 
reveals that residues forming the active site make contacts to each  functional 
group of the first galactose residue, but the protein has only  little specificity  for  the 
binding of the residues following the glycosidic linkage (Garman and Garboczi, 
2004). The second domain is a much smaller  antiparallel !-domain formed by  the 
C-terminus of the polypeptide (Garman and Garboczi, 2004).
Galactocerebrosidase (UniProt P54803) catalyses the final glycosidic step in 
catabolism of galactosphingolipids by  hydrolysing the !-glycosidic bond between 
the galactose residue and the ceramide. One of the important substrates is !-D-
galactocerebroside, the principal lipid component of myelin (Nagano et al., 1998). 
Similarly, glucosylceramidase (UniProt P04062) hydrolases glucosylceramide to 
ceramide and glucose (Sarmientos et al., 1986).
Glycoprotein deglycosylation
Glucosidic hydrolysis of the glycoprotein can start  simultaneously  both from  the 
non-reducing and reducing ends. For complex and hybrid type N-glycans, this 
means removal of any  of the fucose residues attached in the core GlcNAc or in the 
nonreducing end of the glycan by  the enzyme tissue "-L-fucosidase (UniProt 
P04066) (Johnson and Alhadeff, 1991). The glycan residues are removed one by 
")
one from the non-reducing end and many  of the glycosidases catalysing the 
hydrolysis are the same as for other glycoconjugates, but some, such  as lysosomal 
"-mannosidase (MAN2B1, Uniprot O00754) and !-mannosidase (UniProt 
O00462) only catalyse hydrolysis of glycoproteins.
MAN2B1  cleaves "-linked mannose residues from  the non-reducing end of the N-
linked glycoproteins (Tollersrud et al., 1997). The mature human MAN2B1  has 
four disulphide bridges and 11  N-glycans in  its five proteolytic peptides 
(Tollersrud et al.,  1997). Mature MAN2B1  is a dimer with five domains: an active 
site containing an N-terminal "/!-domain, an "-helical bundle and three !-
domains (Table 2)(Heikinheimo et al., 2003). The MAN2B1  structure shows at 
least three interdomain ion bond networks, which could be involved in the low-pH 
activation of the protein (Heikinheimo et al.,  2003). !-mannosidase cleaves the !-
glycosidic bond between mannose and GlcNAc residues (Alkhayat et al., 1998).
The first cleavage in the reducing end is not hydrolysis of a glycosidic bond, but  of 
an amide bond. The N-linked oligosaccharide is cleaved from  the asparagine by  N
(4)-(!-N-acetylglucosaminyl)-L-asparaginase (AGA, Uniprot P20933) (Oinonen et 
al.,  1995), if proteases have already  freed the asparagine(Aronson, 1999). AGA has 
the N-terminal nucleophile (Ntn) amide hydrolase superfamily  fold (Table 2) and 
a threonine residue as the N-terminal nucleophile (Oinonen and Rouvinen, 
2000). It  has two N-glycans, onto both of which  M6P tag can be added (Tikkanen 
et al., 1995). "-N-acetylgalactosaminidase (UniProt P17050) catalyses the removal 
of the terminal "-N-acetylgalactosamine residue of the O-linked sugars attached 
to the serine or threonine residues of O-glycosylated proteins (Clark and Garman, 
2009).
2.3.2.3 Lipases
Several phospholipases with different target bond activity  or substrate specificity 
act in  lysosomes. Group XV phospholipase A2  (Uniprot Q8NCC3) is a Ca2+-
independent lipase that hydrolyses phosphatidylcholine and phosphatidyl-
ethanolamine (Hiraoka et al., 2002). Phospholipase D1  (UniProt Q13393) 
hydrolyses phosphatidylcholine to phosphatic acid and choline and has a  role in 
exocytosis (Vitale et al., 2001).
Sphingomyelins contain a phosphocholine or phosphoethanolamine group 
attached to ceramide. Sphingomyelin phosphodiesterase (UniProt P17405) 
converts sphingomyelin  to ceramide (Irvine et al.,  1978).  Acid ceramidase 
(UniProt Q13510) hydrolyses ceramide to sphingosine and free fatty  acid (Gatt, 
1963; Bernardo et al., 1995).
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Cholesteryl esters are hydrolysed by  lysosomal acid lipase/cholesteryl ester 
hydrolase (Uniprot P38571) (Du et al., 1998) and cholesterol is transported back 
to the cell membrane or to the ER (Möbius et al., 2003).
The full degradation of lipid containing molecules requires additional hydrolases 
such  as palmitoyl-protein thioesterase 1  (UniProt P50897) (Bellizzi et al.,  2000), 
which removes fatty acyl groups from cysteine residues in lipid-modified proteins.
2.3.2.4 Phosphatases, nucleases and sulphatases
Lysosomes contain at least  two acid phosphatases: lysosomal acid phosphatase 
(Uniprot P11117) and the tartrate resistant acid phosphatase type 5 (UniProt 
P13686) (Suter et al.,  2001). Lysosomal acid phosphatase is synthesised as a 
membrane bound precursor and proteolytically  released in lysosomes. Both 
enzymes are monoesterases with a role in the removal of the M6P recognition 
marker from lysosomal proteins (Makrypidi et al., 2012).
The primary  nuclease in lysosomes is deoxyribonuclease-2-" (UniProt O00115), 
which is proteolytically  processed and activated in the lysosome (Ohkouchi et al., 
2013). It is proposed to be the key  enzyme in the degradation of apoptotic nuclei 
(Howell et al., 2003).
Compared to the phosphatases and nucleases,  lysosomal sulphatases are relatively 
well characterised. They  catalyse the hydrolysis of sulphate ester  bonds. Four 
lysosomal sulphatases are known, of which three, arylsulfatase A (UniProt 
P15289),  arylsulfatase B (UniProt  P15848) and N-acetylgalactosamine-6-
sulphatase (GALNS, UniProt  P34059) are soluble. They  are paralogous proteins 
with ~30 % sequence identity to each other.
The structures of all three are known and the overall folds are highly  similar 
(Bond et al., 1997; von Bülow et al.,  2001; Rivera-Colón et al.,  2012). They  are 
homodimers, where each monomer consists of three domains (Table 2)(Rivera-
Colón et al.,  2012). The active site domain has a core !-sheet, which  is surrounded 
by  "-helices. The active site is located in  the center of the domain and has a 
modified cysteine residue that is required for  activity. The second domain has an 
antiparallel !-sheet.  The smallest domain is a”C-terminal meander”, in which the 
last  41  residues form a loop structure stretching along the side of the active site 
domain and then threading half-way back towards the starting point of the loop.
Despite the structural similarity  and the fact that these three enzymes have 
overlapping activities in vitro, they  are non-redundant in vivo (Rivera-Colón et 
al.,  2012).  The main substrate of arylsulfatase A is a cerebroside 3-sulphate 
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(Lukatela et al.,  1998). Arylsulfatase B is involved in  the degradation of 
mucopolysaccharides such as dermatan sulphate. It hydrolyses the 4-sulphate 
groups in the N-acetylgalactosamine 4-sulphate residues of these molecules 
(Haskins et al.,  1979). GALNS removes the 6-sulphate groups from  the terminal 
N-acetylgalactos-amine-6-sulphate in mucopolysaccharides such as keratan 
sulphate (Rivera-Colón et al., 2012). The substrate specificity  of the sulphates 
arises from the different  overall sizes, shapes and electrostatistics of the active site 
pockets (Rivera-Colón et al., 2012).
2.3.2.5 Phospholipase B-like proteins
In mammals, the PLBD1  and PLBD2 genes encode paralogous soluble proteins 
with  unknown cellular  functions. These proteins, phospholipase B-like protein  1 
(PLBD1, UniProt Q6P4A8 for the human protein) and phospholipase B-like 
protein 2  (PLBD2, UniProt Q8NHP8), are conserved and have homologs in 
several higher eukaryotes. They  do not exist in plants, fungi or  prokaryota. The 
sequence identity  between human PLBD1  and PLBD2 is approximately  30 %. 
They  also both  have ~30 % sequence identity  to a Dictyostelium discoideum 
phospholipase B-like protein (UniProt Q550U9).
The phospholipase B-like protein family  is named after  the amoeba protein which 
was shown to have low phospholipase B (PLB) activity  (Morgan et al., 2004). PLB 
proteins hydrolyse fatty  acids both  from the sn1  and sn2 positions in 
glycerophospholipids (Figure 4) (Lee et al., 1994). So far, the Dictyostelium 
discoideum  protein has remained the only  phospholipase B-like protein that has 
been shown to have PLB or indeed any  other type of enzymatic activity  (Jensen et 
al., 2007; Deuschl et al., 2006).
PLBD1  is a soluble glycoprotein that was first  purified from  human secretory 
lysosomes (Xu et al.,  2009). It  has also been identified in several proteomic 
studies of lysosomal proteins (Sleat et al.,  2005; Sleat et al., 2008; Della Valle et 
al.,  2011; Chen et al., 2009). Furthermore, the human PLBD1  contains M6P-
residues (Sleat et al., 2008), which is why  it was considered a candidate lysosomal 
protein (Schröder et al., 2010).
The human neutrophile derived PLBD1  formed two fragments on SDS-PAGE with 
molecular weights of 22 kDa  and 42  kDa. After preincubation for  several weeks, 
the protein showed PLB activity, but significantly  lower than that  reported for 
other PLBs. Xu et al (2009) proposed that preincubation is necessary  for  the 
activation of the 42  kDa fragment and that activation requires a  proteolytic cut in 
N- and C-terminus of the 42 kDa fragment.
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catalysis (Oinonen and Rouvinen, 2000). This catalytic N-terminal nucleophile is 
created autoproteolytically  from the precursor  protein. The N-terminal 
nucleophile can be either a threonine,  serine or cysteine residue and its "-amino 
group works as a catalytic base in the reaction. The preserved stereochemistry  of 
the active site suggests that all  Ntn-hydrolases share the same catalytic 
mechanism (Oinonen and Rouvinen, 2000).
The proposed lipase function for the PLBD family  is inconsistent with the Ntn-
fold, since all the other Ntn-family  enzymes cleave amide not ester  bonds 
(Oinonen and Rouvinen, 2000).
2.3.2.6 Lysosomal !-glucosidase
Lysosomal "-glucosidase (GAA Uniprot  P10253,  also known as acid "-
glucosidase) is the sole enzyme in lysosomes responsible for degrading glycogen to 
glucose (Kroos et al.,  2012). GAA is unrelated to the enzymes of the cytosolic 
glycogen degradation (see below) and it  hydrolyses both "(1->4) and "(1->6) 
glycosidic bonds, unlike the cytosolic glycogen phosphorylase.
Glycogen molecules are large multi-branched polymers of glucose (Figure 5). 
Glycogen is an efficient, quickly-mobilised form of energy  stored in animal cells 
(Roach et al.,  2012). Glycogen is principally  made and stored in liver and muscle 
cells, where it is the main energy  source in high intensity  exercise (Romijn et al., 
1993). Enzymatic dephosphorylation of glucose is required for glucose release 
through  the cell membrane (Roach et al., 2012). Thus only  liver  cells can 
participate in regulation of blood glucose levels,  as only  they  can release D-glucose 
back into the blood stream.
Cellular  glycogen is stored in the cytosol as granules,  which  consist  of a single 
glycogen molecule and complement proteins. The complement proteins are 
responsible for  the autonomous synthesis and breakdown of each glycogen 
molecule (Shearer and Graham, 2004). In addition to the classic cytosolic 
breakdown, where glycogen is cleaved through glucose-phosphate derivatives, 
glycogen is converted directly  to glucose in  lysosomes. Lysosomal degradation 
requires that some of the cytosolic glycogen is transported to lysosomes. The exact 
mechanism  of the transport is still unclear  (Raben et al., 2008),  but it  is proposed 
to resemble selective autophagocytosis (Jiang et al., 2010).
Lysosomal degradation of glycogen is crucial for  cells. The glycogen storage 
disease type II, Pompe disease, is caused by  mutations in the GAA gene. 
Insufficient GAA activity  causes progressive accumulation of glycogen in 
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122-199) and a 70 kDa peptide (residues 204-782). The 3.9  kDa peptide is thus in 
the mature 70 kDa form attached by  a  disulphide bridge to the 10.4 kDa peptide 
instead of the largest peptide (Moreland et al., 2005).
The 76/70 kDa forms have been reported to have a  7-10 increase in glycogen 
affinity  compared to the 110 kDa precursor form, and it has been thus suggested 
that proteolytic processing is needed for optimal enzymatic activity  (Wisselaar  et 
al., 1993; Bijvoet et al., 1998).
GAA is an exohydrolase and by  sequence similarity  belongs to the glycoside 
hydrolase family  31  (GH31). GH31  enzymes are a heterogeneous group of 
glycoside hydrolases that have broad activities and a wide range of substrate 
specificities (Henrissat  and Davies, 1997). For instance, the human sucrase/
isomaltase, human intestinal maltase-glucoamylase and "-galactosidase (GLA) 
are all GH31  enzymes. The N-terminal domain of the intestinal maltase-
glucoamylase (UniProt O43451) has 44% sequence identity  with GAA and its three 
dimensional structure has been solved (PDB 2QLY) (Sim et al., 2008). The 
catalytic residues of GH31  enzymes include two aspartic acids,  one functioning as 
a nucleophile and the other  as a general acid/base.  The region surrounding the 
aspartic acid residues is conserved in GH31 enzymes (Sim et al., 2008).
The catalytic base in human GAA is Asp518 (Hermans et al., 1991). Asp518 is 
located in the 76/70 kDa peptide of the mature GAA. The structure of GAA is 
unknown, but a GAA homology  model based on the intestinal maltase-
glucoamylase structure suggests that GAA is composed of three domains 
(Bruckmann et al., 2012). In  the model,  the active site of GAA is formed on the top 
of the central ("/!)8 barrel (Bruckmann et al., 2012).
2.4 Significance of lysosomes in human health
Due to the indispensable role of degradation and recycling for cell  homeostasis 
and for the various more specific lysosomal roles, proper function of the lysosomal 
system is vital for living cells. Failure of lysosomal function has been long  known 
to result in  lysosomal storage disorders (LSDs). In recent years the importance of 
the intact lysosomal pathways has become evident in diseases other than the 
orphan LSD’s.
LSD mutation carriers appear  to be more susceptible to common diseases, such as 
stuttering, dementia, Parkinson’s and Alzheimer’s diseases (Kang et al., 2010; 
Boya, 2012; Nalls et al.,  2013; Avrahami et al.,  2013).  The best studied example of 
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this is the connection between Gaucher  disease and Parkinson’s disease. The 
recessively  inherited Gaucher disease is caused by  mutations in the GBA gene 
encoding a  soluble lysosomal hydrolase, Glucosylceramidase.  Recessive mutations 
in  GBA predispose to Parkinson’s disease and it is in fact  the most  common 
genetic risk factor for  Parkinson’s disease (Tayebi et al., 2003; Sidransky  et al., 
2009; Nichols et al., 2009; Dehay et al., 2013).
The exposure of the link between the LSD mutations and common diseases has 
significance on several levels.  The studies have already  given insight to the 
function of the lysosomal system  and to the mechanism  of the disease pathologies 
of both the LSDs and Parkinson’s disease (Dehay  et al., 2013; Schapira and Gegg, 
2013).
Lysosomal dysfunction has an important role in  the mechanism of Parkinson’s 
disease pathogenesis (Osellame et al., 2013). For instance, the Gaucher disease 
mouse model has shown that dysfunctional mitochondria and insoluble "-
synuclein accumulate to the cytosol of the cell as a result of impaired autophagic 
and proteosomal machineries (Foltynie and Kahan, 2013). These findings open up 
possibilities for  new  therapeutic approaches to Parkinson’s disease and related 
synucleinopathies, such as augmenting glucosylceramidase activity  (Sardi et al., 
2013). Also carriers of the GBA risk mutations could benefit from treatments 
before any Parkinson’s disease symptoms appear (Schapira and Gegg, 2013).
Lysososomes have an important role in the progression of common diseases that 
do not involve identified LSD mutations. For instance, recent studies indicate that 
lysosomal dysfunction caused by  deficient lysosome mediated autophagy  could 
play  a part in the progression of diabetic neuropathy  (Peres et al.,  2013). Thus, 
autophagy  activation is a  possible therapeutic target  for  diabetic neuropathy 
(Kume et al., 2014).
The role of lysosomes in cancer progression is dual. Some of the cancer-associated 
lysosomal changes contribute to tumor  growth and some are tumor suppressing 
(Kallunki et al.,  2013). The expression of cathepsins in vitro  is up-regulated in 
cancer  cells and thus the inhibition of cysteine cathepsins has potential in  cancer 
therapy  (Kallunki et al.,  2013).  For instance, cathepsin B is a  key  contributor to 
bone metastasis and its inhibition significantly  reduces metastasis (Withana et al., 
2012).
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2.4.1 Lysosomal storage disorders
The over 50 known LSDs are inherited diseases that often lead to severe 
disabilities and premature death. They  are caused by  a mutation in  a  single gene 
encoding a lysosomal or  lysosome related protein (Hopwood, 2012). Common to 
all LSDs is impaired lysosomal degradation and the subsequent progressive 
storage of unhydrolysed material or digestion products in lysosomes. This results 
in  damage to multiple cellular systems and tissues (Platt et al., 2012; Cox and 
Cachon-Gonzalez, 2012). LSDs are often grouped according to the chemical nature 
of the primary  storage material and these groups include for  instance lipidoses, 
mucopolysaccharidoses and neuronal ceroid lipofuscinoses.
The individual LSDs are rare diseases, but collectively  they  form significant  group 
of inherited diseases, which affect 1  out of every  7700 newborn children (Meikle et 
al.,  1999). The mode of inheritance in  most LSDs is autosomal recessive, but some 
such as Fabry disease have X-linked inheritance.
In a classical LSD, the disease is caused by  mutations in a  gene encoding a 
lysosomal hydrolase and the material building up to lysosomes is the substrate of 
this hydrolase. Pompe disease, "-mannosidosis, Morquio A syndrome, 
aspartylglucosaminuria, Gaucher’s disease, Fabre’s disease and sialidosis are 
examples of classical LSDs. Reduced or  missing protein activity  in lysosomes can 
occur in several ways, related to the type of the disease-associated mutation. The 
mutation can prevent the synthesis the hydrolase, lead to truncated protein, 
prevent correct folding of the enzyme or  lead to a protein with disturbed active 
site (Kuokkanen et al., 2011; Rivera-Colón et al., 2012). In addition, the protein 
may  be insufficiently  transported or  unstable in lysosomes (Kuokkanen et al., 
2011; Rivera-Colón et al., 2012).
However,  as LSDs form  a diverse group of diseases (Hopwood, 2012), even the 
‘classic’ LSDs cannot be considered as ‘typical’ LSDs.  In several LSDs, the gene 
containing an LSD-associated mutation, encodes for a  protein, which is not a 
lysosomal hydrolase, but a  protein related to the formation or function of 
lysosomes (Sleat et al.,  2009). Some LSDs have still unknown etiology  (Sleat et 
al.,  2009). Thus the compounds accumulating  in the lysosomes are not  always 
substrates of a  single lysosomal hydrolase. In Salla disease the protein with 
impaired function is a  transporter  (Aula et al., 1979). Sialic acid, which builds up 
in  lysosomes in Salla disease,  is an end product of lysosomal hydrolysis, which is 
not transported further (Mancini et al., 1991).
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Mucolipidoses II and III are caused by  impairement  in the lysosomal targeting 
machinery. GlcNAc phosphotransferase is required for addition of M6P-tag  and 
thus for transport of most lumenal lysosomal proteins to lysosomes.  It is a 
heterohexameric complex formed of three subunits; ",  ! and #. Mucolipidosis II is 
caused by  pathogenic mutations in the gene GNPTAB encoding GlcNAc 
phosphotransferase " and ! subunits (Tiede et al.,  2005). Because of the impaired 
GlcNAc phosphotransferase function, the lysosomal activity  of most lysosomal 
hydrolases is affected in Mucolipidoses II (Hickman and Neufeld,  1972). 
Mutations of the GNPTG gene encoding the soluble #-subunit  are associated with 
the clinically less severe mucolipidosis III (Raas-Rothschild et al., 2000).
Gradual accumulation of lysosomal storage material in  LSDs disturbs the function 
of the whole cell by  a complex mechanism, which involves a  cascade of numerous 
secondary  cellular effects triggered by  the storage of the material (Cox and 
Cachon-Gonzalez, 2012). In most  LSDs,  the lysosomal storage of the material 
occurs in all cell types, but depending on the disease, some organs and tissues are 
more affected than others (Boustany,  2013). The clinical manifestations of LSDs 
differ widely  between different disorders, but often  heart bone,  muscle, liver, 
kidney  and spleen are affected.  Approximately  2/3  of all LSD patients have central 
nervous system  involvement  and progressive neurodegeneration (Micsenyi and 
Walkley, 2012).
Due to the heterogeneity  of the disease-associated mutations and the multi-organ 
involvement in many  LSDs,  even patients with the same LSD have variation in the 
clinical symptoms. Most  LSDs include an early,  more severe and a  late, milder 
form of the disease. In the early  form, accumulation of compounds in the 
lysosome starts at  birth or in early  childhood. The early  onset phenotypes often 
lead to death at an early  age. In the late onset phenotypes, the lysosomal storage 
material appears more slowly  and the symptoms can appear during childhood or 
during adulthood.
LSDs are characterised by  low enzyme activity  in the lysosomes of the patients 
cells. Each tissue type has a disease specific threshold for  enzyme activity  and 
under  this threshold the effects of the mutation are pathogenic (Marsden and 
Levy, 2010). Enzyme activity  measurement of patient isolated cultured fibroblasts, 
is often  used in diagnosis and in prediction of the prognosis of the disease 
(Winchester, 2012).  In general, early  onset  patients have no or very  little enzyme 
activity,  although low activity  may  also be connected with  late onset patients 
(Willemsen et al., 1993). Depending on inherited mutation  and patient phenotype, 
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even a moderate therapeutic increase in the lysosomal enzyme activity  can 
significantly improve the quality of life for the patient.
In genotype-phenotype correlation, mutations which cause large disturbance to 
the protein  structure or mutations which directly  affect the active site residues, are 
usually  early  onset  causing phenotypes. However, direct linking of the genotype to 
the phenotype, may  be challenging (Kroos et al., 2012). Especially,  distinction of 
late onset disease-associated mutations from  polymorphism  is difficult (Desnuelle 
and Salviati, 2011). This is an important issue in progressive diseases, as many  late 
onset  patients would benefit from early  treatment, before the first symptoms 
emerge (Toscano et al., 2013). Disease prevention has great potential in the 
future,  as more LSD mutations are screened on population level from newborn 
babies (Labrousse et al., 2010; Marsden and Levy, 2010; Yang et al., 2014) or 
when more carriers of the LSD mutations are linked with common diseases of the 
elderly (Nichols et al., 2009; Dehay et al., 2013).
2.4.1.1 Pompe disease
Pompe disease, also known as glycogen storage disease type II, was the first LSD 
described (Hers, 1963). Its mode of inheritance is autosomal recessive. Mutations 
in  the GAA gene encoding lysosomal "-glucosidase cause impairment of the GAA 
activity  in the lysosomes. GAA activity  of Pompe patients can be either severely 
lowered or  completely  absent (Beratis et al., 1978; Kroos et al., 2008). Insufficient 
GAA activity  leads to lysosomal accumulation of the GAA substrate, glycogen 
(Hers, 1963; van der Ploeg and Reuser, 2008).
Like in other  LSDs, the birth prevalence of Pompe disease varies by  population. 
Predictions of the birth  prevalence are between 1  in 40 000 newborns in the 
Netherlands (Ausems et al., 1999) and 1  in  600 000 newborns in Northern 
Portugal (Pinto et al., 2004). In Finland, only  three Pompe disease cases have 
been diagnosed (Vanto et al., 1982; Korpela et al., 2009) suggesting that the birth 
prevalence of Pompe in  Finland is much lower than the overall estimated 
prevalence of Pompe disease in Western countries (Korpela et al., 2009).
The symptoms of Pompe disease are caused mainly  by  damage of cardiac, skeletal 
and smooth muscle (van den Hout et al., 2003). Unlike LSDs in general, Pompe 
disease less frequently  affects the central nervous system  (Boustany, 2013). An 
important  contributor to the muscle weakness is the disordered intracellular 
recycling  system. This does not  involve only  the lysosomal degradation, but also 
UPS and phagocytosis are affected (Raben et al., 2008).
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Early  age onset Pompe patients have symptoms before the age of one and there is 
cardiac involvement, which  is absent in late onset patients (Kroos et al.,  2008). In 
the late onset  Pompe phenotypes,  the symptoms mainly  include progressive 
muscular weakness,  which appears during childhood or during adulthood (Kroos 
et al., 2012).
2.4.2 Current therapies for lysosomal storage disorders
Most treatments for LSDs still  concentrate on managing  the disease-associated 
symptoms, but several disease-specific treatments have emerged over  the past  two 
decades (Parenti et al., 2013).
One of the first  disease-specific treatments,  which is still in use, was hemopoietic 
stem cell transplantation (Giugliani et al.,  2010). In 1980,  the first bone marrow 
transplant was done to a  Mucopolysaccharidose I patient to endogenously  supply 
the deficient "-L-iduronidase with a  normal one (Hobbs et al., 1981). The 
treatment depends on finding suitable healthy  bone marrow donors 
(Valayannopoulos and Wijburg, 2011).
In gene therapy, as in hemopoietic stem cell transplantation, the aim  is to restore 
the lysosomal enzyme activity  endogenously  by  introducing a normal copy  of the 
defected gene into a subset of the patient’s cells (Parenti et al., 2013). Several 
methods, such  as transfecting  the patient’s cells by  viral vectors (Seregin and 
Amalfitano, 2011), or  replacing subset of a  specific cell type with genetically 
corrected stem  cells or  microencapsulation technique (Boelens and Wynn, 2013), 
have been tested for the gene transfer. In all these cases, the transfected cells will 
provide a systemic pool of the correct  enzymes (Boelens and Wynn, 2013). The 
development of gene therapy  has been successful in many  animal tests,  but also 
encountered problems, such as the immunogeneity  produced by  the viral vectors 
(Seregin and Amalfitano, 2011). Thus the great potential of gene therapy  has not 
yet  been successfully  turned into an approved treatment in any  of the LSDs 
(Parenti et al., 2013).
In enzyme replacement therapy  (ERT), the deficient enzyme is replaced 
exogenously. The intravenously  introduced recombinant enzyme is targeted to 
lysosomes through the M6P-receptors on the cell surface (Brady, 2006).  ERT is an 
approved treatment  for six LSDs and is in developmental stage for several more 
(Ohashi, 2012). In Gaucher disease and in Fabry  disease, ERT became available in 
1991  and in 2001  respectively  and for Mucopolysaccharidosis types I, II and VI in 
2003, 2007  and 2006 (Glamuzina et al., 2011; Wraith et al., 2005; Lourenço and 
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Giugliani, 2014). For  Pompe disease, ERT with recombinant human GAA (rhGAA, 
Myozyme) was approved in  2006. It  is still the sole treatment for Pompe disease 
(van den Hout et al., 2001; Kishnani et al., 2007).
ERT prolongs life and reduces symptoms of the Pompe patients especially  among 
early  onset  patients when treatment is started early  (Kishnani et al., 2007). In 
adult patients as well, the treatment improves the skeletal function to some extent 
and prevents respiratory  failure (van der  Ploeg et al., 2010; Orlikowski et al., 
2011), even though clearance of the stored glycogen is not as effective as in early 
onset  patients. This is partly  thought to be because the impaired phagocytosis 
caused by the prolonged storage of glycogen (Raben et al., 2008).
The high  price and other  drawbacks of ERT has led to interest in  alternative 
treatments. In substrate reduction therapy, the biosynthetic pathway  of the 
substrate of the defective enzyme is inhibited with small molecules to reduce the 
amount of the substrate (Valayannopoulos and Wijburg, 2011). Substrate 
reduction therapy  is especially  valuable in diseases which have strong central 
neurosystem involvement, as the blood-brain barrier creates difficulties for drug 
delivery, especially  of the large recombinant proteins used in  ERT (Boustany, 
2013).
Enzyme enhancement therapy  (EET) is another treatment involving small 
molecules (Porto et al., 2009). Most LSD associated mutations cause 
destabilisation of the target protein fold and lead to the ERAD degradation of the 
newly  synthesised enzyme. In EET, competitive inhibitors work as chemical 
chaperones stabilising the protein  molecules containing destabilising mutations 
and thus prevent  their premature degradation (Fan, 2008). EET is in clinical trials 
for Fabry disease and Gaucher disease (Shayman and Larsen, 2014).
EET has shown great potential for Pompe disease. Several competitive inhibitors 
of GAA could function as a base for  drug development for Pompe (Porto et al., 
2009; Yoshimizu et al., 2008; Flanagan et al.,  2009; Parenti et al., 2007). In 
addition,  an allosteric, not a  competitive inhibitor, could be for  the first  time used 
as a chemical chaperone in EET on GAA (Porto et al., 2012). EET has several 
advantages in the treatment  of Pompe disease in comparison to ERT. It is much 
cheaper, admitted orally  and reaches all organs more equally  than rhGAA. In 
cases where the disease-associated mutation is located in  the active site and EET 
does not  thus increase the residual lysosomal GAA activity, it can be used in 
combination with  ERT to stabilise the recombinant enzyme and decrease the 
amount of needed rhGAA (Porto et al., 2009; Porto et al., 2012).
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3 Aims of the study
For  the present study, I worked with two soluble lysosomal proteins and with an 
analysis of known structures of soluble lysosomal proteins. When the work was 
initiated, phospholipase B-like protein 1  (PLBD1) was not well characterised: its 
lysosomal targeting was only  hypothesised and its function was unknown. The 
second target protein in this study, acid "-glucosidase (GAA), has been previously 
extensively  studied, not least because it  is mutated in Pompe disease. Despite this, 
no three dimensional structure was known for GAA or its close relatives.
The aims of the study were:
-To crystallise and solve the structure of bovine PLBD1 and human GAA.
-To propose a function for the PLBD1 protein and the lysosomal PLBD family.
-To understand the relationship between rhGAA and its competitive inhibitors to 
propose suitable chaperone lead compounds for GAA.
-To better understand the structural basis of lysosomal protein structure and their 
targeting to lysosomes.
-To analyse the molecular mechanism of lysosomal storage disorder associated 
mutations. 
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4 Methods
4.1 Methods used in studies I-III
Methods used in this thesis are listed in Table 3.  Detailed descriptions can be 
found in the original publications I-III. The method for protein crystallisation, 
which is unpublished work, is described in section 4.2.
Table 3. Methods used in the original publications.
Method Study
Protein analysis Protein purification II
SDS-PAGE I, II
Protein concentration measurements I, II
N-terminal sequencing II
Deglucosylation II
Enzyme activity assay I
Thermal stability 
measurements
Differential scanning fluorimetry I, II
Subcellular localisation Immunofluorescence microscopy II
Bioinformatics Sequence comparisons II, III
Surface exposure evaluation for residues III
Secondary structure assigments III
Ligand docking I
X-ray Crystallography Crystallisation II
Molecular replacement II
Model building and refinement II
Structural alignment II, III
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4.2 Crystallisation of recombinant human GAA
The recombinant  human GAA (rhGAA, Myozyme) is a 110 kDa  precursor  form  of 
the enzyme, which is used in enzyme replacement therapy  of Pompe patients. It 
was a gift from Genzyme corporation and was shipped to us in a lyophilised form. 
Upon resolubilisation with water, rhGAA had a concentration of 5 mg/ml and was 
in  a protein buffer containing 25 mM sodium  phosphate pH 6.2,  2 % mannitol, 
0.005 % polysorbate 80.
The crystallisation conditions of rhGAA were screened using the automated 
protein crystallisation facility  at the Institute of Biotechnology  (http://
www.biocenter.helsinki.fi/bi/xray/automation/). In some crystallisation trials, 
the resolubilised rhGAA was concentrated from  the original 5 mg/ml to 15 mg/ml 
and was in others exchanged into 0.02 M sodium acetate pH 4.3. In  all 
crystallisation trials,  the protein was filtered through a 0.22 µm filter (Millipore) 
prior  to crystallisation. The best diffracting crystals grew from a reservoir solution 
containing 0.1  M Tris pH 7, 11  % glycerol, 28% PEG 600 and 0.5 M ammonium 
sulphate with the protein solution containing 7  mg/ml rhGAA in 0.02 M sodium 
acetate pH 4.3. Crystals were flash cryocooled in cryoloops (Molecular 
dimensions) for data collection.
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5 Results and discussion
5.1 bPLBD1 is a lysosomal Ntn-hydrolase (Study II)
Previous proteomic studies suggested that phospholipase B-like protein 1  is a 
putative lysosomal hydrolase (Sleat et al., 2005; Sleat  et al., 2008; Della Valle et 
al.,  2011; Chen et al., 2009). We investigated the subcellular localisation of PLBD1 
by  confocal microscopy. bPLBD1  overexpressed in CHO and HeLa cells 
extensively  co-localised with the lysosomal marker  LAMP1  in vacuolar structures. 
This further suggests that PLBD1 is a lysosomal protein.
5.1.1 Processing and glycosylation of bPLBD1
I purified PLBD1  from  bovine kidneys. The advantage of isolating  protein from an 
endogenous source was that I could characterise the post-translational 
modifications of the mature bPLBD1  reflecting the situation in vivo. The 
characterisation showed that the 545 residue long bPLBD1  precursor  is 
proteolytically  processed and N-glycosylated for  achieving the mature protein.  On 
a reducing SDS-PAGE experiment,  bPLBD1  formed three major  bands with 
molecular weights of approximately  45 kDa, 22  kDa and 11  kDa (Figure 6A). This 
together with N-terminal sequencing suggested that, in addition to the removal of 
the signal sequence, bPLBD1  is proteolytically  cleaved in two places, resulting in 
the removal of about 19  residues between the N- and C-terminal segments (Figure 
6C). These results are similar  to those obtained with the human neutrophile 
derived PLBD1, which also forms two bands (42 kDa and 22  kDa) on SDS-PAGE 
(Xu et al.,  2009), but disagree in the placement of the proteolytic cuts.  In bPLBD1 
the cuts are only  between the two segments, not in both to the N-and C-terminus 
of the 42 kDa band, as proposed for the human PLBD1.
I did time resolved deglycosylation, where the N-glycans are removed stepwise 
with  PNGase F to study  if all N-glycosylation sites in mature bPLBD1  are utilised. 
PNGase F is capable of removing all types of N-glycans and the experiment 
showed that four  N-glycans from the C-terminal segment and one from the N-
terminal segment were removed (Figure 6B). Thus all five glycosylation sites 
present in the mature bPLBD1 sequence are in use.
I studied the nature of the glycans by  deglycosylating bPLBD1  with 
Endoglucosidases F1, F2 and F3 and Endo Hf and PNGase F.  Endoglucosidases F2 
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5.1.2 bPLBD1 structure
I crystallised the kidney  purified bPLBD1  and solved its X-ray  structure at 1.9 Å 
resolution to an Rwork of 19.0 % and an Rfree of 23.1  % by  using molecular 
replacement and the mPLBD2  structure (pdb 3fbx; Lakomek et al., 2009) as a 
template. The structure containing 491  residues verified the predicted proteolytic 
processing, as there is no electron density  for  the residues which are 
proteolytically  removed between the N- and C-terminal segments. There was one 
complete bPLBD1  molecule per asymmetric unit. Instead of forming separate 
domains, the segments together  create the "!!"-fold of the molecule (Figure 7A). 
The electron density  was visible at least for the first GlcNAc residue of all five N-
glycans (Figure 7A) confirming the N-glycosylation pattern from  the 
deglycosylation studies.  The mature bPLBD1  sequence has 5 cysteine residues and 
four of them form two disulphide bridges, C467-C472 and C471-C468, in the C-
terminal segment (Figures 7A and 7C).
The molecular  mass of bPLBD1  estimated based on the gel filtration  elution 
volume was 130 kDa, which  is significantly  larger  than the calculated molecular 
mass of the mature protein, 58.8 kDa.  If the protein were a dimer with five 
average size N-glycans in both monomers, the calculated molecular mass would 
correspond to that estimated from  gel filtration. By  using the crystal symmetry 
matrices to generate symmetry-related copies of the bPLBD1  molecule, I was able 
to identify  a monomer-monomer  assembly  that has a large enough interface (1133 
Å2), to be considered a  true dimer-interface (Figure 7B). For an area, on the 
surface of a protein, the interface is notably  conserved in the PLBD1  family, 
whereas the corresponding region in the monomeric PLBD2 family  has very  little 
conservation. Thus, the biological unit of bPLBD1 is a dimer.
5.1.3 The Ntn-fold and substrate binding Site
The monomer of bPLBD1  and mPLBD2  have the N-terminal nucleophile 
aminohydrolases (Ntn-hydrolase) superfamily  fold (Figure 7A). In Ntn-
hydrolases, proteolytic cleavage is needed to release the N-terminal amino acid, 
which in the case of PLBD1  is Cys225 (Figure 7A). The N-terminal nucleophile has 
two catalytic roles: as a nucleophile and as a general base (Oinonen and Rouvinen, 
2000). The surroundings of Cys225 in bPLBD1  are very  conserved, which is 
consistent with  the fact that  the active site of Ntn-hydrolases is located around the 
N-terminal nucleophile (Figures 7A and C).  From the bPLBD1  structure, it  is 
evident that  the removal of a peptide approximately  19 residues in length between 
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Penicillium chrysogeum (acyltransferase, pdb 2X1E; Bokhove et al., 2010). Ntn-
hydrolases have great similarities in their  active sites. This allowed identification 
of active site amino acid residues in  addition to the C225 that  are important  for 
catalysis. Typically  the oxyanion hole of the Ntn-hydrolase is formed by  a 
backbone amide and an asparagine N$ atom (Bokhove et al., 2010). The oxyanion 
hole residues in acyltransferase superimposed on Thr300 and Asn399 in bPLBD1. 
In the acyltransferase, the Asp121  backbone amide stabilises the thiolate state and 
the side chain oxygen the positively  charged "-amino group of the N-terminal 
cysteine (Bokhove et al.,  2010). In bPLBD1, Trp245 is located in the same position 
(Figure 7C).
5.1.4 Is the PLBD1 an amidase?
Despite the structural similarity  to other Ntn-hydrolases, I could not deduce the 
bPLBD1  substrate by  active site comparison. The reason for this is that  even 
though key  residues are well conserved,  the active site machinery  of Ntn-
hydrolases is so versatile that it can accomodate a  variety  of different substrates 
and even the acyltransferase is evolutionarily  too distant  to bPLBD1. Nevertheless, 
there is a homologous protein to PLBD1  for  which the function had been 
previously  assigned: the Dictyostelium dictyostelium homolog had been shown to 
have Phospholipase B (PLB) activity  (Morgan et al., 2004). The other  PLBD1  and 
PLBD2 members have also been proposed to be phospholipases based on the 
~30% sequence identity  to the Dictyostelium protein. After  prolonged storage, 
very  low PLB activity  has also been detected for  PLBD1  purified from  human 
neutrophils (Xu et al.,  2009), but not for any  other family  member (Deuschl et al., 
2006; Jensen et al., 2007).
Based on the structural analysis, I believe that despite the detected PLB activities, 
these proteins are not phospholipases, because PLB activity  is inconsistent with 
the protein structures. First  of all,  the bonds that are hydrolysed in all of the 
known Ntn-hydrolase substrates are amide, not ester bonds. The esterase function 
can not be excluded, because ester  bonds are easier  to break than amide bonds. 
Second, in terms of a “perfect  catalyst”(Albery  and Knowles, 1977), the mechanism 
of Ntn-hydrolases, which is not  present in esterases or other  amidases, achieves 
maximum  lowering of the free energy  of the difficult step in amide hydrolysis, the 
activation of the leaving group. This would be wasted on ester  bonds. In Ntn-
hydrolases, the incipient primary  RNH2 leaving group is stabilised by  the 
equivalent primary  amine group of the N-terminal nucleophile and such 
stabilisation is not necessary  for  esterases. Third, even if the PLBD1  substrate 
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would contain an ester bond, phospholipids are not suitable putative substrates 
for PLBD1  because the binding site is incorrect. The orientation of the ester  bond, 
if it were the same as the amide, would place the long hydrophobic tail of the 
phospholipid in  what  in bPLBD1  is a small cavity, about the size of a arginine 
(Study  II Figure 7). In mPLBD2, this acyl group binding cavity  is slightly  larger, 
but  the structural analysis shows that in neither of the proteins is it sterically 
possible to place the phospholipid tail in this cavity. As the PLB activities shown 
by  Morgan et al (2004) is for partially  purified protein and by  Xu et al (2009) only 
after  prolonged storage, it is possible that this is merely  a side reaction for these 
enzymes or due to some impurity.
The substrates for  PLBD1  and PLBD2 proteins are probably  somewhat similar, 
but  not the same, because they  have such large differences in their  substrate 
binding sites. As mentioned above, the acyl group binding cavity  in mPLBD2 is 
larger than in bPLBD1.  Secondly, the other part of the site is in  both proteins a 
fairly  large cleft,  but in mPLBD2, it  is partly  covered by  two loops. The shape and 
the size of the open cleft of the substrate binding site in bPLBD1  suggest that the 
putative substrate could be a  sugar based compound,  such as sialic acid, since it 
has a small enough acyl group to fit into the small cavity.
5.2 Lysosomal proteins have several common features 
(Studies I, II, and III)
The lysosomal lumen creates both  advantages and great  challenges for soluble 
lysosomal hydrolases. The acidic environment in itself facilitates hydrolysis of 
macromolecules and in addition lysosomal hydrolases have optimal enzymatic 
activity  at low pH. On the other hand, the acidic environment  and the presence of 
hydrolytic enzymes is challenging for  all proteins, and the lysosomal enzymes are 
at constant  risk to degrade themselves. The lysosomal lumen thus presents a 
unique environment inside the eukaryotic cell  and lysosomal hydrolases have 
unique features to cope with this.
Soluble lysosomal hydrolases are a group of mostly  unrelated, structurally  and 
functionally  diverse proteins. We chose 39 lysosomal protein structures (Table 4) 
for our structural analysis so that  they  would form  a representative set of soluble 
lysosomal proteins (Study  III).  Selection was done by  choosing all mammalian 
sequences with structural information marked as lysosomal in UniProt 
(Consortium, 2012), limiting to those that also including  signal sequence and 
$#
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Table 4. Fold architecture on soluble lysosomal proteins. Table omitted from Study III.
CATH Architecture 
(number)
Protein Salt 
Bridges
Disul-
phides
Proline 
PP
Clusters
PXP
Orthogonal bundle
(1.10)
Proactivator polypeptide 5 4 - 2
Myeloperoxidase 35 6 2 3
!-barrel (2.40) Cathepsin D 11 4 1 (PPP) -
Cathepsin E* 6 3 2 -
Sandwich (2.60) Epididymal secretory protein E1 1 3 - 3
Distorted sandwich 
(2.70)
Ganglioside GM2 activator 4 4 - 2
"#! barrel (3.20) Hyaluronidase-1* 16 5 - 2
3-layer("!") sandwich 
(3.40)
Lysosomal thioesterease PPT2 10 3 - -
Palmitoyl-protein thioesterase 1 16 3 2 3
Gamma glutamyl hydrolase 8 - - -
Lysosomal protective protein 17 4 1 -
Dipeptidyl peptidase 2 * 18 4 - -
Lysosomal pro-x carboxypeptidase*21 4 - 2
Tripeptidyl-peptidase 1* 29 3 4 5
Proprotein convertase subtilisin * 17 12 3 1
4-layer sandwich(3.60) N(4)-(!-N-acetylglucosaminyl)-L-
asparaginase*
15 4 1 3
Putative phospholipase B-like 1
Putative phospholipase B-like 2* 31 2 2 2
Tartarate resistant acid 
phosphatase type 5
12 1 - 1
"#! complex (3.90) Cathepsin Z 18 6 - -
Cathepsin K 13 3 - -
Cathepsin S 23 3 - -
Cathepsin L1 16 3 - -
Cathepsin H 9 4 1 1
Cathepsin B 21 6 3 1
Cathepsin F 6 3 - -
2-Domains
"#! barrel & sandwich   
(or 2-layer sandwich)
"-N-acetyl galactosaminidase 25 4 2 1
" -galactosidase A 30 5 - -
! -hexosaminidase subunit " 32 3 - 1
! -hexosaminidase subunit ! 35 3 - 1
Glucosylceramidase 23 2 1 -
Galactocerebrosidase* 16 1 PPPP 2
! galactosidase* 32 2 1 4
3-layer("!") sandwich 
& 2-layer sandwich
Arylsulphatase A 32 6 5 2
Arylsulphatase B 36 4 3+PPP 1
N-acetylgalactosamine-6-
sulphatase
41 3 4 1
"#! complex & !-barrel Dipeptidyl peptidase 1 (Cathepsin 
C)
16 5 - 1
3-Domains
"#! barrel & 2x 
sandwich
! glucuronidase 44 - 2 2
5-Domains
"-! barrel, up-down 
bundle, sandwich, 
distorted sandwich & 
sandwich
Lysosomal " –mannosidase* 48 4 3 1
verifying with the help of literature (Sleat et al., 2008; Schröder et al.,  2010) that 
they  were part of lysosomal proteome. In addition, one mammalian structure was 
selected within structures of 70% sequence identity  and if a single protein had 
several structures the full length mature human protein was preferred.
The protein domains of the representative set of soluble lysosomal proteins belong 
to three most common fold classes: mainly  ", mainly  !, or  "-!. The most common 
domain architecture (8 out of 39 proteins) is the 3-layer "!"-sandwich (Table 4).
5.2.1 Thermal stability of lysosomal proteins reflects stability 
against lysosomal conditions (Studies I, II and III)
Lysosomal proteins show often good thermostability. I measured the pH and 
thermal stability  of recombinant human acid "-glucosidase (rhGAA) and bPLBD1 
by  differential scanning fluorimetry, which determines the midpoint of thermal 
unfolding (Tm). Both proteins have relatively  high Tms.  The highest Tm for rhGAA 
was 70.2 °C at pH 7, and for  bPLBD1  74.5 °C at pH 5.0 (Figure 8). Similarly  high 
Tm values have been measured previously  for other lysosomal proteins.  For 
example the Tm of human acid "-galactosidase (GLA) is 60.2 °C at pH 5.2 
(Lieberman et al.,  2009) and lysosomal "-mannosidase (MAN2B1), which  purifies 
together with PLBD1 tolerates temperatures of at  least 60°C (Tollersrud et al., 
1997). However, unlike GLA and MAN2B1, which  have narrow pH-optimum  Tm, 
rhGAA and bPLBD1  are stable over  a wide pH range; from  pH 4  to over 7  (Figure 
8).
Proteins are usually  only  marginally  stable and tend to denature close to the 
growth temperatures of the organism  (Richter  et al., 2010). Therefore, the Tms of 
these lysosomal proteins are significantly  higher than what would be expected for 
mammalian proteins.
The basis for thermostability  of proteins from  thermophiles, micro-organisms or 
viruses that thrive in high temperatures, has been extensively  studied (Szilagyi 
and Zavodszky, 2000; Gromiha et al.,  2013). Amino acid distribution, higher 
number  of salt  bridges and hydrogen bonds (Kumar et al., 2000) and 
oligomerisation (Taka et al., 2005) contribute to the stability of these enzymes. 
It  is not  clear  to what extent the same factors contribute to lysosomal protein 
stability.  Thermostable species are evolved to function in extreme temperatures, 
such  as the optimum temperature of Thermotoga maritima, 80°C (Huber  et al., 
1986). Thermostable proteins are in general more rigid compared to the lysosomal 
$%
hydrolases, which require conformational flexibility  due to their  37  °C working 
environment. What is the structural basis of the stability  of proteins in lysosomal 
lumen?
In the set  of 39  representative lysosomal protein structures analysed in this study 
(III), only  12  proteins have higher than expected proline content. Thus,  unlike in 
many  thermostable proteins, high  overall proline content  does not appear to be a 
common feature of lysosomal proteins. However, multiple PP or  PXP patterns, 
which are located in adjacent regions of the protein  sequence and often on surface 
exposed loops, are common in lysosomal proteins (Table 4). Prolines stabilise loop 
regions by  restricting the number of possible conformations and protect the loop 
regions from proteolysis.
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Figure 8. The pH dependence of the thermal denaturation of rhGAA and bPLBD1. 
A) Stability surface for rhGAA shows Tm plotted as a function of NaCl concentration and 
pH. The following buffers, which were selected to get a representative set of the results, 
are presented on the surface: acetate (pH 3.5, 4, 4.5, 5 and 5.5), MES (pH 6 and 6.5), 
Hepes (pH 7, 7.5 and 8) and borate (pH 8.5) with 0, 40, 80, 160, 240, 320 and 400 mM 
NaCl. B) The pH dependence of bPLBD1 thermal denaturation was measured in a mixture 
of Succinic acid, Sodium Phosphate and Glycine buffers to avoid chemical effect due to 
changing the buffer during titration. Standard error bars are displayed for each data 
point.
A) Copyright (2012) Wiley. Used with permission from (Bruckmann et al, Systematic 
Structure–Activity Study on Potential Chaperone Lead Compounds for Acid !-
Glucosidase, CHEMMEDCHEM and John Wiley & Sons Inc.) B) Copyright (2013) Wiley. 
Used with permission from (Repo et al, Is the bovine lysosomal phospholipase B-like 
protein an amidase?Proteins: Structure, Function, and Bioinformatics and John Wiley & 
Sons Inc.).
Some lysosomal hydrolases such as MAN2B1  have extensive salt  bridge networks 
(Heikinheimo et al.,  2003). However,  a large number of salt  bridges is not 
characteristic for  lysosomal enzymes. There was no significant difference in  the 
number of salt bridges or charged residues in the representative set of protein 
structures compared to human proteins in general.
Lysosomal proteins have features that  are beneficial for  protein stability, but 
which do not  occur in thermophilic bacterial and archeal proteins. The two most 
prominent features are N-glycosylation and disulphide bridges. The N-glycans 
have an important role for lysosomal hydrolases in lysosomal targeting via the 
M6P-dependent  route. In addition, N-glycans stabilise protein structure 
(Wormald and Dwek, 1999; Hanson et al.,  2009) and protect them  from 
proteases. All the analysed 39 lysosomal hydrolases have at least one N-glycan. 
The number of N-glycans vary  within the set,  and the number of glycosylation 
sites does not correlate to the length of the polypeptide (Study III, Table I).
Disulphide bridges stabilise the protein fold by  adding a covalent link between 
different secondary  structures (Matsumura  et al., 1989).  All proteins in the 
selected set, except #-glutamyl hydrolase, contain disulphide bridges and most 
proteins contain more than one (Table 3). Like the multiple proline patterns, 
disulphide bridges are typically  on surface areas containing long loop structures. 
In PLBD1  and GLA, disulphide bridges support the wall of the substrate binding 
cleft.
Somewhat surprisingly, although disulphide bridges are common in lysosomal 
proteins, their number  and position are not well conserved in  similar folds, not 
even between homologous proteins. For  example, the disulphide pattern of PLBD1 
and PLBD2 are not conserved, despite the highly  similar monomer structure. 
Similarly, the disulphide bridges in sulphatases are not conserved in all three 
lysosomal sulphatases. Cysteine cathepsins with a similar fold have three to six 
disulphide bridges, of which two are completely  conserved. The non-conserved 
disulphide bridges may  provide additional protection against proteolytic turnover. 
For  example, in the region where cathepsin C lacks one disulphide bridge that 
cathepsins K, S, L1  and F have, cathepsin  C has an additional proteolytic cleavage 
site.
Thermophilic proteins use combinations of several different mechanisms to 
achieve the same stability  (Szilagyi and Zavodszky, 2000). Even related proteins 
can use different mechanisms (Repo et al., 2012). Our work indicates that this is 
$'
true also for lysosomal proteins. Only  a few structural features providing stability 
are shared by all or even related lysosomal proteins.
5.2.2 M6P-dependent transport signal (Studies II and III)
The intriguing enigma of the M6P-dependent  transport signal arises from the 
following. The GlcNAc phosphotransferase recognises large number (over 50) of 
the newly  synthesised soluble lysosomal proteins, which however lack a universal 
and evolutionary  conserved structural recognition motif.  Nonetheless, recognition 
by  the GlcNAc phosphotransferase is specific only  to lysosomal proteins and to a 
few secreted proteins (Reitman and Kornfeld, 1981; Dahms et al., 2008).
5.2.2.1 Conservation of the lysosomal transport signals (Study III)
I first  analysed the conservation of the N-glycosylation sites in the four lysosomal 
proteins, which have been experimentally  verified to contain M6P and where the 
recognition signal for GlcNAc phosphotransferase is known. Phosphorylated N-
glycosylation sites in  cathepsin  D (Dittmer et al.,  1997) are conserved in 22  (N134) 
and in 23 (N263) of the 23  known mammalian sequences; in cathepsin L N221 
(Cuozzo et al.,  1998) is found in all 12 known sequences; in  AGA both sites (N38 
and N308) (Tikkanen et al., 1995) are conserved in 20/22  mammalian sequences; 
and in  arylsulfatase A both sites (N158 and N350) (Yaghootfam  et al.,  2003) are 
conserved in all 20 known mammalian sequences. Thus, the site of the 
phosphorylated glycan seems to be well preserved.
I then similarly  studied the conservation of the lysine residues known to affect the 
N-glycan phosphorylation levels in these proteins. In arylsulfatase A, the only 
lysine residue known to affect  phosphorylation, K457  (Yaghootfam  et al.,  2003), is 
conserved in all 20 known mammalian orthologous sequences. However, six other 
lysine residues in arylsulfatase A sequence are equally  well conserved. In contrast, 
in  cathepsin D two out of the three most important lysine residues are well 
conserved (K267  in 20/21  and K331  in 21/21) but the third (K357) only  in 12 
sequences. K267  is the most important  lysine to modulate phosphorylation of 
cathepsin D conserved glycan at N263  (Steet et al.,  2005). In cathepsin L,  which  is 
not  related to cathepsin D, all five lysine residues that affect phosphorylation are 
conserved in 11  or 12 of the 12  known sequences. The AGA lysine residues (K177, 
K183, K214) are conserved in all or almost all sequences.
Are the well conserved phosphorylated glycosylation sites or lysines also 
conserved in  other  proteins with similar  structure? K457  in arylsulfatase A is also 
conserved in the paralogous arylsulfatase B, but has no significance on 
$(
arylsulfatase B phosphorylation (Yaghootfam  et al., 2003). The location of the N-
glycans in the overall fold is similar in these two sulphatases, but the glycosylation 
sites are not conserved in sequence. This lack of N-glycosylation conservation 
might explain why  K457  is not  important for arylsulfatase B phosphorylation. 
Comparison of cathepsin L structure to the other  cysteine cathepsin  structures 
reveals that the N-glycosylation and surface lysine locations are conserved only  in 
the closest  relative in the protein family, cathepsin V.  Cathepsin L and V have ~70 
% sequence identity  and they  share N-glycosylation at N221. In addition, 
cathepsin V has another glycosylation site. K54 and K99, which are part of the 
cathepsin L GlcNAc phosphotransferase signal, are present in both proteins. 
Unfortunately, there is not  yet  evidence of the significance of these lysines for 
cathepsin V lysosomal localisation.
Some elements of the lysosomal transport  signal, such as the phosphorylated N-
glycans, are well conserved within mammalian sequences of an individual protein. 
Lysine residues, although on the generally  less conserved protein surface, are also 
surprisingly  well conserved. Most lysines are conserved in almost all mammalian 
sequences and thus the lysine residues that are part  of the recognition signal, do 
not  substantially  stand out. Less-conserved lysines, which are part of the 
recognition signal, usually  contribute only  to the phosphorylation  level, but  are 
not  part  of the minimally  required recognition pattern. The recognition signal is 
conserved only  in very  closely  related proteins, and not necessarily  in other 
proteins with  a  similar fold, as shown by  the cysteine cathepsin family,  where only 
the very  similar cathepsins L and V share all the components of the recognition 
signal.
The lysine residues included in  the recognition  pattern are located in varying 
secondary  structure elements, such  as in a !-hairpin,  an "-helix,  a !-strand, in a 
disulphide supported loop and even in the propeptide region. Apart from the 
propeptide lysine in cathepsin L, all important lysines are located on non-flexible, 
well supported areas.  One of the lysine residues is typically  in close proximity  to 
the phosphorylated glycan, but I found no universal distances between the lysine 
residues and the (phosphorylated) N-glycan, as previously  suggested (Cuozzo et 
al.,  1998; Warner  et al., 2002).  Arylsulphatase A is an exception because only  one 
lysine residue is known to affect  binding of the GlcNAc phosphotransferase 
(Yaghootfam et al., 2003).
In cathepsin L, it was shown that  several glycans can be phosphorylated with 
GlcNAc phosphotransferase binding at only  one site because of the N-glycan 
%*
flexibility  (Warner et al., 2002). This would explain why  precise lysine to N-glycan 
distances are not necessary  on the protein surface. It also seems evident that 
proteins with  several phosphorylated N-glycans that  are located on distant parts 
of the protein structure must have several GlcNAc phosphotransferase recognition 
motifs. For  example, in cathepsin D, the known recognition signal affects 
phosphorylation of only  one of the N-glycans (Steet et al., 2005).  In this respect it 
is understandable that proteins with similar structure, but no conserved 
glycosylation, do not share conserved lysines for  GlcNAc phosphotransferase 
recognition.
5.2.2.2 Putative transport signal of the phospholipase B-like proteins 1 
and 2 (Study II)
One of my  main interests in  the the bPLBD1  structure was to identify  surface 
features on bPLBD1  that might be part of the GlcNAc phosphotransferase 
recognition site. bPLBD1  most likely  follows the M6P- dependent pathway  as it 
was shown in this study  to carry  only  non-complex type glycans and was 
previously  shown to contain M6P-glycan (Sleat et al.,  2008). Based on the protein 
structure bPLBD1 has such a large number (32) of surface exposed lysine residues, 
that it prevents identification the important lysine and N-glycan residues by 
analysing the bPLBD1  structure alone. However, the existence of the paralogous 
protein structure, mPLBD2 (PDB 3FBX; Lakomek et al., 2009), offered a  chance 
to identify the most conserved residues.
bPLBD1  and mPLBD2 have one N-glycan,  N408 (N441  in mPLBD2), which is 
conserved in both families in  sequence and structure (Figure 9A). Thus they  could 
share lys ine residues important for  recognit ion by  the GlcNAc 
phosphotransferase. In addition, the N-glycans that are not conserved between 
the two PLBDs have a  similar distribution on the protein surface (Figure 9). Some 
glycosylation sites (N305 in bPLBD1  and N236  in mPLBD2) cluster close to the 
conserved N408 and could be phosphorylated with the same GlcNAc 
phosphotransferase binding area.
bPLBD1  and mPLBD2 have only  one surface lysine in common (K358 in bPLBD1). 
This is located 33-37  Å away  from  the conserved N408(N441) glycosylation site 
and is a  good candidate for the distal lysine of the recognition signal. As there are 
no lysine residues conserved between the families, I then searched for lysine 
residues that are conserved within the families and located in the structural region 
between K358 and N408. There were two such lysine residues in each protein, 
K342  and K334  in bPLBD1, and K372  and K418 in  mPLBD2. All four lysine sites 
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5.2.3.1 Distribution of the disease-associated mutations among the 20 
amino acids
The disease associated missense mutations were unevenly  distributed among the 
20 amino acids. The relative frequency  of the mutations did not  reflect  the 
abundance of the individual amino acid in the protein sequence (Figure 10A).
Most frequently  the disease associated mutations affected glycine, arginine, 
leucine, proline and aspartate residues (Figure 10A). Leucine occurs among 
mutations less frequently  than expected based on the sequence abundance in all 
but  the MAN2B1  enzyme (Study  III, Supplementary  Figure I). Leucine is most 
often (in 35 out of 69 mutations) replaced by  proline. In addition to leucine, 
disease-associated mutations occur  less frequently  than expected at  other small 
and core forming hydrophobic residues,  such as alanine, valine, isoleucine and 
phenylalanine (Figure 10A).
Contrary  to leucine,  glycine and arginine associate with a disease much more often 
than expected based on their abundance in sequences (Figure 10A, Study  III, 
Supplementary  Figure I).  In three of the four cases, glycine is the most frequently 
mutated site (Supplementary  Figure I). In addition,  glycine has several sites that 
contain more than one type of mutation (Figure 10B). In about  one third of the 
mutations glycine residue is replaced by arginine.
Although arginine is not a common residue in protein sequences, arginine 
disease-associated mutations are common and clearly  more frequent than would 
be expected in  all four proteins (Figure 10A, Study  III Supplementary  Figure I). 
Typically, arginine sites also contain more than one type of mutation (Figure 10B). 
Arginine residues are replaced by  cysteine, histidine, glutamine, proline and 
tryptophan with almost equal frequency in about ten of the 69 arginine mutations.
In addition to glycine and arginine, some low  abundance amino acids, such as 
tryptophan, cysteine and methionine, occur more frequently  than expected among 
disease associated mutations.
Proline and cysteine disease-associated mutations are more common than 
expected in all but GALNS (Study  III Supplementary  Figure 3) and the proline 
mutations are among the three most common mutations in two of the four 
proteins (Study  III Supplementary  Figure 3). Proline is most often replaced by 
leucine. Cysteine mutations are especially  common in GLA (Study  III 
Supplementary Figure 3).
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Figure 10. The distribution of LSD-associated mutations. A)The overall distribution of 
amino acid types in the four lysosomal protein sequences (black bars) and in disease-
associated mutations (grey bars). B) The number of residues that contain more than one 
type of different disease associated mutations. The analysed proteins were !-galactosidase 
A (GLA), lysosomal !-glucosidase (GAA), N-acetylgalactosamine-6-sulphatase (GALNS) 
and lysosomal !-mannosidase (MAN2B1).
Aspartic acid and histidine disease-associated mutations show great variation in 
how they  appear in the list of the disease-associated mutations in the individual 
proteins. Aspartic acid mutations occur frequently  only  in GLA, where they  are not 
only  over-represented but  also the second most common type of mutation (Study 
III Supplementary  Figure 3).  In addition, aspartic acid sites in GLA are mutated to 
many  different types of residues (Study  III Supplementary  Figure 2). Similarly, 
histidine mutations are clearly  over-represented in MAN2B1, but not in other 
proteins (Study III Supplementary Figure 3).
5.2.3.2 Structural analysis of the most common mutation types
I analysed the five most  common types of disease-associated missense mutations 
in  protein structures, in order to understand how they  interfere with the protein 
function.
The ratio between surface exposed and buried residues varies from  one residue to 
the next (Table 6). Residues containing disease associated mutations are more 
often among buried residues than the residues of that amino acid in general 
(Table 6).  This is especially  evident in arginine and glycine residues, which in 
general are found more often on the protein surface, but the residues with  disease 
associated mutations are mainly  buried. In contrast,  leucine in general is found 
buried in the protein core. The leucine residues with mutations are even more 
buried than the leucine residues in general.
The tendencies of each amino acid to be located to a certain type of secondary 
structure are reflected in the mutation data  so that distribution of the mutated 
residues in secondary  structure elements, compared to distribution of the same 
amino acid in general, are similar (data not  shown). In other  words, certain 
secondary  structure types do not occur  more often among the mutated residues 
than the secondary  structure occurs among all residues. Arginine,  glycine and 
proline mutations are typical in loop regions even though  in  MAN2B1, the sites 
with  arginine mutations are equally  divided between the three secondary  structure 
elements (Table 6). Of the five amino acids, leucine is the one most equally 
distributed between the different secondary structure elements (Table 6).
In addition, the distribution between the different functional areas of the protein 
shows features typical for each amino acid, especially  for  aspartic acid. Most of the 
aspartic acid, but also glycine residues, associated with LSDs are located in  the 
active site area (Table 6). Instead leucine mutations do not occur prominently  in 
the active site area, but are found on domain and dimer interfaces or  locations 
other than the active site and interfaces (Table 6). Proline and arginine mutations 
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are distributed quite evenly between the different functional areas (Table 6).
5.2.3.3 Structural consequences of the disease-associated mutations
The structural analysis suggests that glycine, arginine, proline,  aspartic acid, 
cysteine and histidine are over-represented among the disease associated 
mutations, because they  have unique features that are difficult to replace by  other 
residues.
These features may  reflect the overall protein where the mutations occur. For 
instance aspartic acid and histidine, where disease associated mutations are both 
over-represented only  in one protein each (GLA or  MAN2B1) are typically  primary 
active site residues (Table 6). This also explains their high frequency  among 
disease association in GLA and MAN2B1. Seven out of the 14  aspartate mutation 
sites in GLA are located in the active site. Similarly, all three histidine mutations 
in  MAN2B1  are in the active site.  Disease associated glycine mutations are also 
often found in  the active site, where the glycine is next to a primary  active site 
residue. The replacement of glycine will almost always disturb the geometry  of the 
active site.
Due to the small overall number  of active site residues, only  a few disease 
associated mutations locate in the active site. It has been even been proposed that 
LSDs should be considered as protein folding diseases (Rivera-Colón et al., 2012). 
In agreement with this idea, also my  analysis finds most probable disease 
associated mutations in buried residues. In  addition,  mutations on residues in 
domain and dimer interfaces, which  are also buried and dependent on the correct 
conformation, were also common (Table 6). In contrary, disease associated 
mutations of the typically  very  surface exposed residues such  as lysine and 
glutamine are much less frequent than could be expected from  their sequence 
abundance (Figure 10).
A bit surprisingly, leucine and other  hydrophobic,  typically  buried residues are 
less common among the disease associated mutations than could be expected 
based on their abundance in sequence. Hydrophobic amino acids might be 
protected, because point  mutations to a codon for hydrophobic residues often lead 
to its replacement by  another very  similar  residue. The most common type of 
replacing amino acid in the disease associated leucine mutations is proline, which 
is detrimental, because proline disturbs the secondary  structure elements where 
leucine often locates.
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In contrary  to leucine, arginine is not  commonly  replaced by  a single type of 
amino acid,  but the disease associated mutations are distributed to several kinds 
of replacements. This suggest that  the cause of the protein failure is not on the 
replacing amino acid, but in the unique features of arginine, which  are lost. 
Arginine has a  large, charged side chain,  which is capable of forming multiple 
interactions. Arginines often locate in dimer  or  domain interfaces or on protein 
surface regions with long loops where arginine connects secondary  structure 
elements. Arginine is capable of forming salt bridges. Even though the arginine 
sites associated with LSD mutations often participate in  salt bridges, the arginine 
residues with mutations are actually  more often involved in hydrogen bonds than 
in  salt bridges. With hydrogen bonds, arginine makes it  important for the local 
structure that  the arginine side chain has long reach and is capable of making 
several connections. The tolerated arginine mutations in MAN2B1  and GLA 
(p.R118C) are fully  exposed. R118C participates in the salt bridge, which extends 
between two "-helices and is thus not so important for the conformation of the 
area. The MAN2B1 arginine (p.R337Q) is a non-conserved residue.
Glycine is unique in that it  has no side chain, which makes it difficult to replace 
and replacement always increases the residue volume. The lack of side chain 
allows backbone conformations that are not  accessible for other  amino acids. 
Thus, typically  glycine residues with disease-associated mutations are next to 
primary catalytic residues or in loops (Table 6).
Proline has a cyclic side chain, which limits the backbone rotation angles and is 
often required in protein structures where the polypeptide needs to change 
direction. Thus the disease-associated proline mutations occur commonly  in tight 
turns and or loop regions, which explains why  they  are common on surface 
exposed residues. As with  arginine, proline sites associated with LSDs include 
several different types of replacing amino acids,  suggesting that  the loss of proline 
is a more important  contribution to protein failure than introduction of the 
replacing residue. In the buried sites with disease-associated proline mutations 
there was often no space for the replacing amino acid side chain. Though the 
surface exposed sites with  proline mutations could often accommodate the side 
chain of the replacing amino acid,  the correct conformation of the polypeptide 
backbone could not be achieved with the replacing amino acids. A significant 
proportion of the proline residues with  disease-associated mutations are in the 
active site area (Table 6).
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Mutations in cysteine residues seem inevitably  disease associated. In GLA, all ten 
cysteine residues which participate on disulphide bridges, also contain disease 
associated mutations. This is in agreement with the fact that disulphide bridges 
are extremely  important for  protein structure. In GLA, many  of the disulphide 
bridges are on loops close to active site. In GALNS,  the disease associated cysteine 
mutation is at C79, which has the formylglycine modification and thus works as 
nucleophile in the active site (Bojarova and Williams, 2008).
5.2.3.4 Towards understanding therapies of lysosomal storage 
disorders
The effectivity  of many  LSD therapies depend on the type of the individual disease 
associated mutation. For  instance, due to the immune response,  enzyme 
replacement therapy  can be less effective in  patient that have no detectable level of 
the endogenous protein (Brooks et al., 2003). Enzyme enhancement therapy  is 
often successful when the disease-associated mutation  affects folding of the 
enzyme and thus causes premature degradation in ER or in lysosomes. Usually 
mutations that cause relatively  mild late onset phenotype respond well to 
chaperone therapy. Typically  for these mutations, the chemistry  or  volume of the 
resulting residue is not significantly  different from the original residue.  However, 
a significant portion of the severe classic Fabry  phenotype associated mutations 
respond to EET (Benjamin et al., 2009), as long as the mutations do not severely 
disturb folding. Examples of mutations, which do not respond to EET , are on 
residues, which are responsible for  the maintenance of the ("/!)8 barrel fold ,such 
as p.L131P (Benjamin et al., 2009).
Active site mutations are problematic for  EET for two reasons. As the chemical 
chaperones are usually  competitive inhibitors they  bind to the same area as the 
substrate, but if mutation interferes with substrate binding, also chaperone may 
bind  poorly.  p.D92N/Y in GLA is an example of non-responsive substrate binding 
mutations (Benjamin  et al., 2009). If the mutation directly  affects the catalytic 
residues, substrate or chaperone binding might occur and the protein is 
transported to lysosomes, but it has no activity. However, also mutations on active 
site area may  be responsive to EET. For example MAN2B1  mutation p.H72L, 
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which affects the metal binding residue in  the active site,  is responsive to Zn2+ 
treatment in patient cultured fibroblasts (Bach et al., 1978).
The effects of the chaperone compounds can be surprisingly  long range. Missense 
mutations in  C-terminal domain or on domain interfaces are common among GLA 
disease-associated mutations (Table 5). Some of these are located quite far away 
from the active site, where the chaperone molecule binds, yet all  the tested GLA 
mutations in the C-terminal domain or domain interfaces responded to the 
chaperone treatment (Benjamin et al., 2009). 
This rises two thoughts. Firstly  the development of EET would greatly  benefit 
from better understanding the stabilising mechanism  of the chaperones as this 
would help to understand, what type peripheral mutations could be treated with 
EET. Secondly, more compounds like N-acetylcysteine, which stabilise GAA, but 
does not bind to the active site (Porto et al., 2012) should be developed as they 
might rescue mutations in  the substrate binding area, which interfere with 
binding of the small substrate derived chaperones, but might still bind the more 
complex natural substrates in lysosomes.
5.3 Understanding of ligand binding is a prerequisite 
for chaperone design
5.3.1 Crystallisation of lysosomal !-glucosidase (unpublished 
results)
The three dimensional structure of GAA could be beneficial in many  ways. With 
the available structure,  we could better  understand the catalytic mechanism of 
GAA. It would also help to directly  analyse the molecular mechanism of Pompe 
disease mutations and be advantageous in developing the existing ERT 
preparations and in finding novel pharmacological chaperones for EET.
I was able to produce rhGAA crystals only  after I changed the protein buffer from 
a phosphate to a sodium acetate buffer. Crystals appeared in a week as thick 
hexagonal rods, with  the longest dimension being 20-50 micrometers.  The best 
crystals diffracted X-rays to 6Å.  However, the diffraction pattern  was diffuse and 
determination of the space group or cell parameters was not  possible. I made 
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several attempts to improve the diffraction by  optimising the crystallisation 
conditions or by  growing the crystals in presence of the GAA inhibitors 
deoxynojirimycin and acarbose.  Unfortunately  the crystal quality  was not 
improved by  optimisation, and the protein did not crystallise at all in the presence 
of inhibitors.
5.3.2 Systematic study of chaperone lead compounds for 
lysosomal !-glucosidase (Study I)
The potential of enzyme enhancement therapy  (EET) for treatment of Pompe 
disease has been shown previously  using individual inhibitors (Porto et al.,  2009; 
Yoshimizu et al., 2008; Flanagan et al.,  2009; Parenti et al.,  2007). In order to 
study  the GAA chaperone lead compounds systematically, I selected a series of 12 
inhibitors (Figure 11) representing most of the available GAA competitive 
inhibitors. I used Myozyme as an enzyme preparation in my  study  because, apart 
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Figure 11. Inhibitors grouped by Ki values. Background colours identify the gradient 
from lower to higher Ki values. We studied the binding of 13 GAA inhibitors. The binding 
of conduritol "-epoxide was non-competetive and it had low potential as a chaperone lead 
compound, it was therefore discarded from the rest of the study.
Copyright (2012) Wiley. Used with permission from (Bruckmann et al, Systematic 
Structure–Activity Study on Potential Chaperone Lead Compounds for Acid !-
Glucosidase, CHEMMEDCHEM and John Wiley & Sons Inc.)
from the cleavage of the signal sequence, it  is proteolytically  unmodified and thus 
resembles the precursor  form  of GAA in the ER. In addition it is used in enzyme 
replacement therapy  and EET could be used in combination with that to stabilise 
the recombinant enzyme.
5.3.2.1 rhGAA stability is improved by several inhibitors
To compare the rhGAA stabilisation capacity  of the inhibitors,  I measured by 
differential scanning fluorimetry  the effect  of the inhibitors on rhGAA thermal 
unfolding at 14  different concentrations. Because an effective chaperone molecule 
is required to bind to GAA in the ER, rhGAA thermal stability  was measured both 
at the acidic lysosomal pH (pH 4.3) and at  neutral pH (pH 7.0 and pH 7.5) (Figure 
12A). The thermal unfolding of rhGAA in the absence and presence of the 
inhibitors was surprisingly  consistent at all  pHs tested. Several inhibitors were 
capable of stabilising rhGAA, and all of them  except isofagomine increased the 
unfolding temperature of rhGAA (Figure 12).
The stabilisation effect  of the inhibitors appeared to be based on specific binding 
as the rhGAA Tm increased as a function of inhibitor  concentration. D-Galactose, 
on the other  hand, which is a stereoisomer of D-glucose but does not bind to the 
GAA active site, had no effect on rhGAA Tm.  There were great  differences in the 
stabilisation capacities of the different inhibitors. Castanospemine produced the 
highest  rhGAA Tms at  all concentrations and only  2.4 µM of it was needed for the 
rhGAA Tm to be as high  as 70°C,  while a concentration of 212  mM of D-glucose 
was required to achieve the same effect (Figure 12C and D).
The inhibitors split into two groups, strong and weak, based on their capacity  to 
stabilise rhGAA. These groups remained the same when inhibitors were assigned 
according to their inhibition constants. There was thus a clear  correlation between 
inhibition and stabilisation. To better compare the stabilisation capacities of the 
individual inhibitors, I also measured the rhGAA Tm at a concentration of 10 times 
the Ki of each inhibitor (Table 7),  thus comparing the stabilisation effect of the 
inhibitors under equivalent conditions.
These concentrations gave sufficient  binding and the shifts in Tm were on 
measurable scales.  Shifts in the rhGAA Tm at these concentrations showed that the 
stabilisation capacity  of an  inhibitor  is related to its Ki,  but the stabilisation 
capacity  could not be derived from  the Ki since the order of strength of inhibition 
is not the same as the order  of stabilisation capacity.  For  instance the strongest 
inhibitor, deoxynojirimycin (DNJ), was the weakest  stabiliser in  the group of 
strong inhibitors.  Especially  interesting  compounds were castanospermine and 
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structure of the N-terminal domain of human maltase-glucoamylase (MGA, pdb 
2QMJ; Sim  et al.,  2008) was used as a template for the model. The active site is 
very  conserved in the glycoside hydrolase family  31  and I could mainly  adopt the 
GAA active site residue conformations and the overall  binding modes of acarbose 
and miglitol from  the MGA-ligand co-crystal structures (acarbose pdb 2QMJ and 
miglitol pdb 3L4W (Sim et al., 2010a)) (Figure 13). The binding modes of the 
inhibitors chemically  similar to acarbose,  voglibose,  D-turanose and D-glucose, 
were modeled based on the predicted binding mode of acarbose to GAA and the 
inhibitors chemically  similar to miglitol,  DNJ and its analogs, fagomine and 
isofagomine, were modeled based on the miglitol binding mode.
In the model, the binding of the inhibitors to GAA is oriented by  four hydroxyl 
groups. Acarbose is bound to the GAA active site from its acarvosin end (Figure 
13A). Asp404, Asp518, His674 and Asp616 are directly  hydrogen bonded to the S1 
ring  hydroxy  groups of acarbose. In addition, Asp645 stabilises one water 
molecule and Asp443, Asp518 and Trp481  stabilise another water molecule that 
are hydrogen bonded to the hydroxyl groups of the inhibitor (Figure 13A). The 
hydrogen bonding of the piperidine hydroxyl groups of miglitol is similar to that 
of acarbose (Figure 13B) and the other inhibitors share this hydrogen bonding 
pattern. Isofagomine and fagomine are exceptions.  They  lack one of the hydroxyl 
groups and thus also the hydrogen bonding to Asp616.  This missing hydroxyl 
group is the only  difference between the strongest inhibitor, DNJ, and fagomine 
and makes the Ki of fagomine over 500 times larger than that of DNJ.
All ligands except D-glucose and D-turanose contain a secondary  or tertiary  amine 
that is predicted to be charged at neutral pH. Modeling also suggests how  this 
affects binding to rhGAA. In acarbose, the secondary  amine is between the S1  and 
S2  rings and Asp616 forms an ion pair with it (Figure 13A). The amine of voglibose 
is also stabilised by  Asp616. In miglitol, the charged tertiary  amine is located on 
the piperidine ring 2.3 Å away  from the acarbose amine in the superposed 
structure and the charge is stabilised by  Asp518 (Figure 13B). The nitrogen atom 
in  isofagomine is part of the piperidine ring, but  positioned differently  to that of 
miglitol (Figure 11) causing it be located between Asp518 and Asp616 at  hydrogen 
bonding distance to both, but with suboptimal bonding angles to either one. This 
explains why  it is a much weaker inhibitor than fagomine and actually  destabilises 
rhGAA (Table 7, Figure 12D). The inhibitors lacking the secondary  or tertiary 
amine, D-glucose and D-turanose,  are the weakest of all the inhibitors. 
Conversely, the strongest inhibitors have the charged nitrogen atom  in the 
piperidine ring.  Interestingly, even though voglibose has the nitrogen similarly 
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positioned outside the ring as acarbose,  the Ki of voglibose is in the same range as 
that of miglitol.
This work showed by  thermal stability  studies that  rhGAA can be stabilised by 
several inhibitors that  have varying stabilisation capacities. I demonstrated that 
the inhibitors also stabilise destabilised rhGAA. In addition,  we showed that  in a 
cellular  environment, the most promising compounds improve the trafficking of 
variant  GAAs to lysosomes. By  combining the information  gained from  the 
modeling of the ligand binding with the inhibition studies, we suggest three 
factors that contribute to the tightness of the ligand binding on GAA and that 
should be considered when designing a chemical chaperone compound for GAA. 
Firstly, four  well-positioned hydroxyl groups are needed to orient the ligand and 
make the binding specific. Secondly, as the natural substrate of GAA is a large 
molecule, glycogen, but very  small inhibitors also bind tightly, the substrate 
binding cleft allows the binding  of both small and large molecules. Thirdly, the 
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Figure 13. Superposition of the active residues of GAA and MGA. GAA residues are 
presented in black and MGA residues in grey. Conserved ligand binding hydrogen bonds 
are emphasised with thicker lines. Neutralisation of the ligand charge is marked with + 
and – signs. The conformation of W376, which is not conserved in MGA, was taken from 
the structure of sucrose isomaltase (pdb 3LPO; Sim et al., 2010b). (A) Acarbose binding. 
(B) Miglitol binding.
Copyright (2012) Wiley. Used with permission from (Bruckmann et al, Systematic 
Structure–Activity Study on Potential Chaperone Lead Compounds for Acid !-
Glucosidase, CHEMMEDCHEM and John Wiley & Sons Inc.)
existence of a  positive charge in the ligand and its location is the most  important 
binding determinant.
In Pompe disease as in many  other  LSDs, EET with  chemical chaperones is a 
promising treatment option, that  is expected to help especially  patients with the 
late onset form of the disease. The potential of EET for  Pompe has been shown in 
in vitro studies (Yoshimizu et al., 2008), in cultured Pompe disease patient 
fibroblasts (Parenti et al., 2007) as in Pompe disease mouse model (Khanna et al., 
2012). However, most of the studies concentrate only  on a few putative chaperone 
compounds and useful data for developing more specific and possibly  pH sensitive 
chaperone compounds, has been limited.
In this study, we systematically  tested several putative chaperone compounds for 
GAA. Differential scanning fluorimetry  is a good method in order  to compare the 
stabilisation capacity  of the inhibitor, as it  directly  gives information on thermal 
stabilisation of the target protein (rhGAA). Importantly, the measurements can be 
done also in neutral pH,  which resembles the pH in the ER lumen, where in vivo 
the compounds would bind the mutated GAA. In  addition, comparable rhGAA 
binding data with several compounds and modelling of the compounds to the GAA 
homology  model, helped us to understand factors which determine the ligand 
binding strength.  Combining the information should help in design of new 
chaperone lead compounds.
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6 Conclusions and future perspectives
Lysosomes are ubiquitous cell  organelles in higher eukaryotes,  and they  form the 
main degrading compartment in cells.  In addition to recycling cellular 
components, they  are involved in  numerous biological functions. Lysosomal 
dysfunction is not only  important in the individually-rare lysosomal storage 
disorders, but has also been recognised as a  causative agent of other very  common 
neurodegenerative diseases such  as Parkinson’s disease. Understanding the 
cellular  function of lysosomes is thus crucial.  This cannot be achieved without 
comprehending the main functional component of the lysosome, the lysosomal 
proteins.
The purification of bPLBD1, analysis of its post translational modifications and 
determination of its three dimensional structure have increased the knowledge of 
this protein. First of all, I showed that bPLBD1  is a soluble lysosomal hydrolase 
and that its glycosylation pattern contained high  mannose glycans. The structure 
revealed that PLBD1  is an amidase. The putative substrate must have a small acyl 
group, but the rest of the substrate can be large and contain for example sugar 
moieties. This is in contrast to earlier reports,  which suggest low phospholipase 
activity  to the partially  purified hPLBD1  derived from  neutrophils (Xu  et al., 
2009).
Determination of the cellular  function and native PLBD substrate would help in 
understanding if the PLBD-family  is involved in an LSD of yet unknown aetiology. 
Identification of the PLBD substrates could be addressed in several ways. For 
instance, the correct molecule type could be searched for  by  virtual screening with 
molecular docking of suitable compounds with the amide bond. In my  study  we 
show  that bPLBD1  has a regular thermal unfolding curve and thus, the candidate 
compounds could be screened for  by  differential scanning fluorimetry. The 
binging and native substrates could later be verified with enzyme activity assays.
The central undetermined aspect  of M6P-dependent transport  is the exact  nature 
of the GlcNAc phosphotransferase recognition motif. I showed that the asparagine 
and lysine residues, which are part of the recognition site,  are well conserved on 
the mammalian orthologous proteins, but not necessarily  conserved in the fold 
superfamily. For bPLBD1,  I was able to propose a likely  candidate for the 
primarily  phosphorylated N-glycan and the lysine residues which  potentially 
monitor GlcNAc phosphotransferase binding. These findings need to be 
experimentally  verified. Mutagenesis combined with cellular  localisation studies 
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could be used to test the significance of these lysine residues for  the transport of 
PLBDs to the lysosome.
Current treatments for LDSs are highly  specific and often very  expensive. Enzyme 
replacement therapies, when they  exist,  are not accessible for all patients, and also 
have limited effect on different types of the individual disease. Enzyme 
enhancement has shown great potential as a  new treatment, and could possibly 
also be developed for Pompe disease.  However, applying EET to Pompe disease 
would benefit  from a wider  range of stabilising compounds than currently  known. 
I thus systematically  studied " glucosidase inhibitors to understand the molecular 
determinants for  effective inhibitor  binding on rhGAA. The study  showed that the 
stabilisation capacities of the different inhibitors vary  greatly  and do not correlate 
with  Ki. Docking the compounds to a rhGAA homology  model provided a sound 
structure-functional basis for development of new  chemical chaperones. These 
studies should be continued,  for  instance by  synthesis of related compounds as 
novel chaperones.  A crystal structure of rhGAA with ligands, would increase the 
precise understanding of binding. Novel designed molecules should first be 
screened both in vitro for their ability  to stabilise rhGAA, as well  as by  ex vivo to 
confirm the increased levels of GAA variants in  chaperone treated cells. This 
would suggest that the chaperones could also be active in vivo.
Individual lysosomal storage disorders are orphan diseases and the disease 
associated mutations typically  private, io. unique to a family. In late onset cases, 
with  mutation carriers or in the screening of new-borns, it is difficult to know if a 
certain mutation is disease-associated or  nonpathogenic. However, early 
treatment,  even before the first  symptoms emerge, would be beneficial to prevent 
serious complications. Better  understanding of the general molecular mechanism 
by  which  the mutations affect lysosomal protein transport, folding  or function will 
provide a  better  way  of predicting the mutation severity. My  analysis of the 
general trends of disease associated mutations will hopefully  help researches and 
clinicians to evaluate the severity  of novel mutations and also to recognise 
potential carriers, who are at risk to develop diseases of the elderly, such as 
Parkinson’s.
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